Document:

<PAGE>
                                                                    EXHIBIT 10.1

                           J. ALEXANDER'S CORPORATION
                  FORM OF 2005 INCENTIVE STOCK OPTION AGREEMENT

         THIS INCENTIVE STOCK OPTION AGREEMENT (this "Agreement") is made and
entered into as of this 21st day of December, 2005 (the "Grant Date"), by and
between J. Alexander's Corporation, a Tennessee corporation (together with its
Subsidiaries and Affiliates, the "Company"), and __________________ (the
"Optionee"). Capitalized terms not otherwise defined herein shall have the
meaning ascribed to such terms in the J. Alexander's Corporation 2004 Equity
Incentive Plan (the "Plan").

         WHEREAS, the Company has adopted the Plan, which permits the issuance
of stock options for the purchase of shares of the common stock, par value $.05
per share, of the Company (the "Shares"); and

         WHEREAS, the Company desires to afford the Optionee an opportunity to
purchase Shares as hereinafter provided in accordance with the provisions of the
Plan;

         NOW, THEREFORE, in consideration of the mutual covenants hereinafter
set forth and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the parties hereto, intending to
be legally bound hereby, agree as follows:

         1.       Grant of Option.

                  (a)      The Company grants as of the date of this Agreement
the right and option (the "Options") to purchase the following numbers of
Shares, in whole or in part (the "Option Stock"): ___ Shares at an exercise
price of $8.22 per Share and ___ Shares at an exercise price of $9.50 per Share,
on the terms and conditions set forth in this Agreement and subject to all
provisions of the Plan. The Optionee, holder or beneficiary of the Option shall
not have any of the rights of a shareholder with respect to the Option Stock
until such person has become a holder of such Shares by the due exercise of the
Option and payment of the Option Payment (as defined in Section 3 below) in
accordance with this Agreement.

                  (b)      The Option shall be an incentive stock option within
the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the
"Code"), and this Agreement shall be interpreted in a manner consistent
therewith. In order to provide the Company with the opportunity to claim the
benefit of any income tax deduction which may be available to it upon the
exercise of the Option, and in order to comply with all applicable federal or
state tax laws or regulations, the Company may take such action as it deems
appropriate to insure that, if necessary, all applicable federal, state or other
taxes are withheld or collected from the Optionee.

         2.       Exercise of Option; Restrictions on Resale. The Optionee may
exercise the Option at any time after the date hereof. In consideration for the
Option, the Optionee agrees not to sell, contract to sell, grant any option to
purchase, transfer the economic risk of ownership in, make any short sale of,
pledge or otherwise transfer or dispose of any Shares (or any interest in any
Shares) (the foregoing are defined as the "Resale Restrictions") until December
21, 2007.

                                       1
<PAGE>

Notwithstanding the foregoing, in the event the Optionee's employment or service
with the Company is terminated for any reason, 100% of the Shares underlying the
Options shall become free from the Resale Restrictions on the effective date of
termination.

         3.       Manner of Exercise. The Option may be exercised in whole or in
part at any time within the period permitted hereunder for the exercise of the
Option, with respect to whole Shares only, by serving written notice of intent
to exercise the Option delivered to the Company at its principal office (or to
the Company's designated agent), stating the number of Shares to be purchased,
the person or persons in whose name the Shares are to be registered and each
such person's address and social security number. Such notice shall not be
effective unless accompanied by payment in full of the Option Price for the
number of Shares with respect to which the Option is then being exercised (the
"Option Payment") and cash equal to the required withholding taxes as set forth
by Internal Revenue Service and applicable State tax guidelines for the
employer's minimum statutory withholding. The Option Payment shall be made in
cash or cash equivalents or in whole Shares that have been held by the Optionee
for at least six months prior to the date of exercise valued at the Shares' Fair
Market Value on the date of exercise (or next succeeding trading date if the
date of exercise is not a trading date), together with any applicable
withholding taxes, or by a combination of such cash (or cash equivalents) and
Shares. The Optionee shall not be entitled to tender Shares pursuant to
successive, substantially simultaneous exercises of the Option or any other
stock option of the Company. Subject to applicable securities laws and the
Resale Restrictions, the Optionee may also exercise the Option by delivering a
notice of exercise of the Option and by simultaneously selling the Shares of
Option Stock thereby acquired pursuant to a brokerage or similar agreement
approved in advance by proper officers of the Company, using the proceeds of
such sale as payment of the Option Payment, together with any applicable
withholding taxes. The Optionee shall notify the Company of any disposition of
shares acquired under this Agreement if such disposition occurs within two years
after the date of grant or one year after the date of exercise of the Option.
For purposes of this Agreement, "Fair Market Value" means the closing sales
price of the Shares on the American Stock Exchange.

         4.       Termination of Option. The Option will expire ten years from
the date of grant of the Option (the "Term") with respect to any then
unexercised portion thereof, unless terminated earlier as set forth below:

                  (a)      Termination by Death. If the Optionee's employment by
the Company terminates by reason of death, or if the Optionee dies within three
months after termination of such employment for any reason other than Cause,
this Option may thereafter be exercised, to the extent the Option was
exercisable at the time of such termination, by the legal representative of the
estate or by the legatee of the Optionee under the will of the Optionee, for a
period of one year from the date of death or until the expiration of the Term of
the Option, whichever period is the shorter.

                  (b)      Termination by Reason of Disability. If the
Optionee's employment by the Company terminates by reason of Disability, this
Option may thereafter be exercised, to the extent the Option was exercisable at
the time of such termination, by the Optionee or personal representative or
guardian of the Optionee, as applicable, for a period of three years from the
date of such termination of employment or until the expiration of the Term of
the Option,

                                       2
<PAGE>

whichever period is the shorter; provided, however, that if the Option is
exercised following the one-year anniversary of the date of termination, the
Option shall thereafter be treated as a Non-Qualified Stock Option. For purposes
of this Agreement, "Disabled" or "Disability" means that the Optionee is
permanently unable to perform the essential duties of the Optionee's occupation.

                  (c)      Termination by Normal Retirement or Early Retirement.
If Optionee's employment by the Company terminates by reason of Normal
Retirement or Early Retirement, this Option may thereafter be exercised by the
Optionee, to the extent the Option was exercisable at the time of such
termination, for a period of three years from the date of such termination of
employment or until the expiration of the Term of the Option, whichever period
is the shorter; provided, however, that if the Option is exercised following the
three-month anniversary of the date of termination, the Option shall thereafter
be treated as a Non-Qualified Stock Option. "Early Retirement" means retirement,
for purposes of the Plan with the express consent of the Company at or before
the time of such retirement, from active employment with the Company prior to
age 65, in accordance with any applicable early retirement policy of the Company
then in effect. "Normal Retirement" means retirement from active employment with
the Company on or after age 65.

                  (d)      Termination for Cause. If the Optionee's employment
by the Company is terminated for Cause, this Option shall terminate immediately
and become void and of no effect.

                  (e)      Other Termination. If the Optionee's employment by
the Company terminates voluntarily or is involuntarily terminated for any reason
other than for Cause, death, Disability or Normal Retirement or Early
Retirement, this Option may be exercised, to the extent the Option was
exercisable at the time of such termination, by the Optionee for a period of
three months from the date of such termination of employment or the expiration
of the Term of the Option, whichever period is the shorter.

         5.       No Right to Continued Employment. The grant of the Option
shall not be construed as giving Optionee the right to be retained in the employ
of the Company, and the Company may at any time dismiss Optionee from
employment, free from any liability or any claim under the Plan.

         6.       Adjustment to Option Stock. The Committee may make adjustments
in the terms and conditions of, and the criteria included in, this Option in
recognition of unusual or nonrecurring events (including, without limitation,
the events described in Section 4.2 of the Plan) affecting the Company or the
financial statements of the Company or of changes in applicable laws,
regulations, or accounting principles, whenever the Committee determines that
such adjustments are appropriate in order to prevent dilution or enlargement of
the benefits or potential benefits intended to be made available under the Plan.

         7.       Amendments to Option. Subject to the restrictions contained in
Sections 6.2 and 14 of the Plan, the Committee may waive any conditions or
rights under, amend any terms of, or alter, suspend, discontinue, cancel or
terminate, the Option, prospectively or retroactively; provided that any such
waiver, amendment, alteration, suspension, discontinuance, cancellation or
termination that would adversely affect the rights of the Optionee or any holder
or beneficiary

                                       3
<PAGE>

of the Option shall not to that extent be effective without the consent of the
Optionee, holder or beneficiary affected.

         8.       Limited Transferability. During the Optionee's lifetime this
Option can be exercised only by the Optionee, except as otherwise provided in
Section 4(a) above or in this Section 8. This Option may not be assigned,
alienated, pledged, attached, sold or otherwise transferred or encumbered by
Optionee other than (i) to a Permitted Transferee or (ii) by will or the laws of
descent and distribution. Any attempt to otherwise transfer this Option shall be
void. No transfer of this Option by the Optionee by will or by laws of descent
and distribution shall be effective to bind the Company unless the Company shall
have been furnished with written notice thereof and an authenticated copy of the
will and/or such other evidence as the Committee may deem necessary or
appropriate to establish the validity of the transfer. Any transfer of this
Option by the Optionee to a Permitted Transferee must be for no consideration
and, after the transfer, the Permitted Transferee shall have the sole
responsibility for determining whether and when to exercise the Option. A
Permitted Transferee may not transfer any such Option other than by will or the
laws of descent and distribution. For purposes of this Agreement, "Permitted
Transferee" means the Optionee's Immediate Family, a Permitted Trust or a
partnership of which the only partners are members of the Optionee's Immediate
Family. For purposes of this Agreement, "Immediate Family" means the Optionee's
children and grandchildren, including adopted children and grandchildren,
stepchildren, parents, stepparents, grandparents, spouse, siblings (including
half brothers and sisters), father-in-law, mother-in-law, daughters-in-law and
sons-in-law. For purposes of this Agreement, a "Permitted Trust" means a trust
solely for the benefit of the Optionee or Optionee's Immediate Family.

         9.       Reservation of Shares. At all times during the term of this
Option, the Company shall use its best efforts to reserve and keep available
such number of Shares as shall be sufficient to satisfy the requirements of this
Agreement.

         10.      Plan Governs. The Optionee hereby acknowledges receipt of a
copy of the Plan and agrees to be bound by all the terms and provisions thereof.
The terms of this Agreement are governed by the terms of the Plan, and in the
case of any inconsistency between the terms of this Agreement and the terms of
the Plan, the terms of the Plan shall govern.

         11.      Severability. If any provision of this Agreement is, or
becomes, or is deemed to be invalid, illegal, or unenforceable in any
jurisdiction or as to any Person or the Award, or would disqualify the Plan or
Award under any laws deemed applicable by the Committee, such provision shall be
construed or deemed amended to conform to the applicable laws, or if it cannot
be construed or deemed amended without, in the determination of the Committee,
materially altering the intent of the Plan or the Award, such provision shall be
stricken as to such jurisdiction, Person or Award, and the remainder of the Plan
and Award shall remain in full force and effect.

         12.      Notices. All notices required to be given under this Option
shall be deemed to be received if delivered or mailed as provided for herein to
the parties at the following addresses, or to such other address as either party
may provide in writing from time to time.

                                       4
<PAGE>

         To the Company:      J. Alexander's Corporation
                              Suite 260
                              3401 West End Avenue
                              Nashville TN 37203
                              Attn:  Chief Financial Officer

         To the Optionee:     The address then maintained with respect to the
                              Optionee in the Company's records.

         13.      Governing Law. The validity, construction and effect of this
Agreement shall be determined in accordance with the laws of the State of
Tennessee without giving effect to conflicts of laws principles.

         14.      Resolution of Disputes. Any dispute or disagreement which may
arise under, or as a result of, or in any way related to, the interpretation,
construction or application of this Agreement shall be determined by the
Committee. Any determination made hereunder shall be final, binding and
conclusive on the Optionee and the Company for all purposes.

         15.      Successors in Interest. This Agreement shall inure to the
benefit of and be binding upon any successor to the Company. This Agreement
shall inure to the benefit of the Optionee's legal representative and assignees.
All obligations imposed upon the Optionee and all rights granted to the Company
under this Agreement shall be binding upon the Optionee's heirs, executors,
administrators, successors and assignees.

         16.      Excessive Shares. In the event that the number of Shares
subject to this Option exceeds any maximum established under the Code for
Incentive Stock Options that may be granted to Optionee, or in the event that
this Option becomes first exercisable in any calendar year to obtain Common
Stock having a Fair Market Value (determined at the time of grant) in excess of
$100,000, this Option shall be treated as a Non-Qualified Stock Option to the
extent of such excess. The proceeding sentence shall be interpreted consistently
with the provisions of Section 422(d) of the Code.

                  [Remainder of page intentionally left blank.]

                                       5
<PAGE>

         IN WITNESS WHEREOF, the parties have caused this Incentive Stock Option
Agreement to be duly executed effective as of the day and year first above
written.

                        J. ALEXANDER'S CORPORATION

                        By:
                            --------------------------------------------------

                        Optionee:

                        ------------------------------------------------------
                        Please Print

                        Optionee:

                        ------------------------------------------------------
                        Signature

                                       6<PAGE>

                                                                    EXHIBIT 10.1

                             JOINT VENTURE AGREEMENT

  [FORMATION AND OPERATION OF BRIDGETECH CRO, INC. AND AMCARELABS CHINA, INC.]

      THIS JOINT VENTURE AGREEMENT (this "AGREEMENT"), effective as of April 10,
2005, is made by and between BRIDGETECH HOLDINGS INTERNATIONAL, INC., a Delaware
corporation ("BRIDGETECH"), and AMCARE LABS INTERNATIONAL, INC., a Delaware
corporation ("AMCARE," together with Bridgetech, the "PARTIES").

                                   WITNESSETH

      WHEREAS, AMCARE is an affiliate of Johns Hopkins International Medical
Laboratories;

      WHEREAS, AMCARE is in the business of providing laboratory medicine and
pathology services in select global markets;

      WHEREAS, BRIDGETECH has developed a network of research and development,
manufacturing and distribution relationships in China;

      WHEREAS, BRIDGETECH and AMCARE wish to form two joint ventures, each in
the form of a new corporation to be organized under the Delaware General
Corporation Law, for the respective purposes set forth below:

            a.    the development and operation of a clinical research
                  organization within China (including Hong Kong) and Taiwan
                  ("NEWCO1"),

            b.    the development and operation of clinical diagnostic anatomic
                  and clinical pathology labs within China (including Hong Kong)
                  and Taiwan ("NEWCO2");

      WHEREAS, Newco1 and Newco2 will each be jointly owned by BRIDGETECH and
AMCARE in accordance with the provisions of this Agreement and the Related
Agreements (defined below), and will be operated in accordance with the terms of
this Agreement and the Related Agreements (defined below).

      NOW THEREFORE, in consideration of the premises and of the mutual
covenants and agreements contained in this Agreement, and for other good and
valuable consideration, the receipt and adequacy of which is hereby
acknowledged, the Parties agree as follows.

1.    The Project.

      1.1   Purpose. The purpose of this Agreement is to set out the basis on
            which the Parties will:

            (a)   form Newco1 to develop, own and operate a CRO within the
                  People's Republic of China, Hong Kong and the Republic of
                  China (Taiwan) (the "TERRITORY"). A "CRO" is an organization
                  that assists biotechnology companies in the research, testing
                  and approval process for products and technologies;

            (b)   form Newco2 to develop, own and operate MTFs within China. An
                  "MTF" is a medical testing facility that provides a full range
                  of anatomic and clinical pathology testing services; and,

                                       1

<PAGE>

            (c)   at such time as BRIDGETECH and AMCARE may mutually agree,
                  expand the activities of Newco1 and/or Newco2 (the "ADDITIONAL
                  BUSINESSES").

            (all such activities being referred to collectively as the
            "PROJECT").

2.    Related Agreements; Timing.

      2.1   Related Agreements.

            (a)   The implementation of the Project will be accomplished in
                  accordance with the terms of this Agreement and also the
                  agreements and other documents referred to in this Section
                  2.1(a) (collectively, the "RELATED AGREEMENTS"). The parties
                  may enter into additional agreements related to the Project
                  from time-to-time, which additional agreements shall become
                  "Related Agreements" if the Parties mutually agree to
                  designate them as such. This Agreement and the Related
                  Agreements are sometimes referred to as the "PROJECT
                  DOCUMENTS".

                  (i)   Newco1 Charter Documents. The Newco1 Charter Documents,
                        as described in Section 3.1(a).

                  (ii)  Newco2 Charter Documents. The Newco2 Charter Documents,
                        as described in Section 3.1(b).

                  (iii) Newco1 Stockholders Agreement. The Newco1 Stockholders
                        Agreement, as described in Section 3.2(b).

                  (iv)  Newco2 Stockholders Agreement. The Newco2 Stockholders
                        Agreement, as described in Section 3.2(b).

                  (v)   Newco1 Management Agreement. The Newco1 Management
                        Agreement, as described in Section 3.5(a).

                  (vi)  Newco2 Management Agreement. The Newco2 Management
                        Agreement, as described in Section 3.5(a).

            (b)   Construction and Interpretation. The Parties acknowledge that
                  the Related Agreements are intended to be consistent with the
                  intent and purpose of this Agreement but agree that to the
                  extent that the provisions of this Agreement conflict with the
                  provisions of any Related Agreement, such Related Agreement
                  will control the relationship of the Parties under that
                  Related Agreement.

      2.2.  Timing.

            (a)   Closing: The Newco1 Certificate and the Newco2 Certificate
                  shall be filed with the Secretary of State of the State of
                  Delaware by BRIDGETECH within 45 days following the date of
                  this Agreement. The closing of the transactions contemplated
                  herein (the "CLOSING") shall occur on such date (the "CLOSING
                  DATE"), at such time and at such location as the Parties may
                  agree. At the Closing:

                  (i)   The appropriate Parties shall execute the Newco1
                        Management Agreement and the Newco2 Management
                        Agreement;

                                       2

<PAGE>

                  (ii)  BRIDGETECH and AMCARE will deliver to one another the
                        Officer's Certificates described in Section 2.2(c)
                        below; and,

                  (iii) BRIDGETECH and AMCARE shall take such other actions and
                        deliver such other documents and instruments as may be
                        necessary or appropriate to effectuate the transactions
                        contemplated herein.

            (b)   Pre-Closing Activity of Newco 1 and Newco 2. Prior to the
                  Closing, it is understood that Newco1 and Newco2 shall not (i)
                  conduct any business operations whatsoever, or (ii) enter into
                  any contract or agreement of any kind, acquire any assets or
                  incur any liabilities, in each case except as may have been
                  approved in writing by BRIDGETECH and AMCARE. If this
                  Agreement is terminated prior to the Closing, Newco1 and
                  Newco2 shall be dissolved.

            (c)   Conditions to Closing. The obligation of each Party to
                  consummate the Closing is subject to satisfaction of each of
                  the following additional conditions as of immediately prior to
                  the Closing:

                  (i)   Newco1 and Newco2 shall have issued stock certificates
                        representing the Bridgetech Shares to BRIDGETECH and
                        shall have issued stock certificates representing the
                        Amcare Shares to AMCARE;

                  (ii)  the Parties shall have executed the Newco1 Stockholders
                        Agreement and the Newco2 Stockholders Agreement;

                  (iii) the Parties shall have negotiated mutually-satisfactory
                        Management Agreements for Newco1 and Newco2;

                  (iv)  there shall be no pending or threatened litigation
                        regarding the Project Documents, Newco1 or Newco2;

                  (v)   there shall have been no material adverse change in the
                        business, properties, financial conditions or prospects
                        of either Party, Newco1 or Newco2 between the date
                        hereof and the Closing Date.

                  Each of AMCARE and BRIDGETECH shall have delivered to one
                  another a certificate from an authorized officer certifying
                  that (A) the representations and warranties of such Party set
                  forth in this Agreement are true and correct as of the Closing
                  Date and (B) the conditions set forth in Sections 2.2(c)(iv) -
                  (v) above have been satisfied (the "OFFICERS' CERTIFICATES").

            (d)   Termination Prior to the Closing. If the Closing shall not
                  have occurred on or prior to June 30, 2005, this Agreement and
                  all obligations of the Parties hereunder, except the
                  obligations under this Section 2.2(d) and Sections 8, 9, 10,
                  11 and 12.7, shall terminate, unless extended by mutual
                  agreement of the Parties; provided, however, that such
                  termination shall not constitute a waiver of any rights any
                  Party have by reason of a breach of this Agreement.

3.    Newco1 and Newco2.

      3.1   Formation.

                                       3

<PAGE>

            (a)   Newco1 shall be formed by the filing of the Certificate of
                  Incorporation in substantially the form attached hereto as
                  Exhibit A (the "NEWCO1 CERTIFICATE") with the Secretary of
                  State of the State of Delaware. The bylaws of Newco1 shall be
                  in substantially the form attached hereto as Exhibit B (the
                  "NEWCO1 BYLAWS," together with the Newco1 Certificate, the
                  "NEWCO1 CHARTER DOCUMENTS").

            (b)   Newco2 shall be formed by the filing of the Certificate of
                  Incorporation in substantially the form attached hereto as
                  Exhibit A (the "NEWCO2 CERTIFICATE") with the Secretary of
                  State of the State of Delaware. The bylaws of Newco2 shall be
                  in substantially the form attached hereto as Exhibit B (the
                  "NEWCO2 BYLAWS," together with the Newco2 Certificate, the
                  "NEWCO2 CHARTER DOCUMENTS").

      3.2   Ownership.

            (a)   Ownership. Each of Newco1 and Newco2 shall be authorized to
                  issue one thousand (1,000) shares of common stock, par value
                  $.001 per share. BRIDGETECH shall initially own six hundred
                  seventy (670) shares of common stock of Newco1 (the
                  "BRIDGETECH NEWCO1 SHARES") and one hundred eighty (180)
                  shares of common stock of Newco2 (the "BRIDGETECH NEWCO2
                  SHARES," together with the Bridgetech Newco1 Shares, the
                  "BRIDGETECH SHARES"). AMCARE shall initially own three hundred
                  thirty (330) shares of common stock of Newco1 (the "AMCARE
                  NEWCO1 SHARES") and eight hundred twenty (820) shares of
                  common stock of Newco2 (the "AMCARE NEWCO2 SHARES," together
                  with the AMCARE Newco1 Shares, the "AMCARE SHARES"). At any
                  given time, the "OWNERSHIP PERCENTAGE" of each Party in Newco1
                  and Newco2 shall be determined by dividing the number of
                  shares of common stock of such entity owned by such Party by
                  the aggregate number of shares of capital stock of such entity
                  outstanding.

            (b)   Restrictions on Transfer. Prior to Closing, BRIDGETECH and
                  AMCARE shall enter into a stockholders agreement with respect
                  to Newco1 (the "NEWCO1 STOCKHOLDERS AGREEMENT") and a
                  stockholders agreement with respect to Newco2 (the "NEWCO2
                  STOCKHOLDERS AGREEMENT"), each in substantially the form
                  attached hereto as Exhibit C. Each person thereafter seeking
                  to own or acquire shares of Newco1 or Newco2 will be required
                  to join the Newco1 Stockholders Agreement or the Newco2
                  Stockholders Agreement, as applicable, as a condition to the
                  issuance of shares to such person, and shall be subject to all
                  the rights and obligations set forth therein. No holder of any
                  equity interest in Newco1 or Newco2 may sell, transfer,
                  assign, pledge or grant or permit any security interest, lien,
                  charge or other encumbrance upon such equity interest without
                  the prior approval of both BRIDGETECH and AMCARE, except as
                  expressly permitted by the Stockholders Agreement.

      3.3   Management.

            (a)   Composition of the Boards of Directors.

                  (i) Newco1 will be managed by a board of directors (the
                  "NEWCO1 BOARD"). The Newco1 Board will consist of three
                  members, of whom two members will be appointed by BRIDGETECH
                  (the "BRIDGETECH NEWCO1 DIRECTORS") and one member will be
                  appointed by AMCARE (the "AMCARE NEWCO1

                                       4

<PAGE>

                  DIRECTOR"; the BRIDGETECH Newco1 Directors and the AMCARE
                  Newco1 Director are referred to collectively as the "NEWCO1
                  DIRECTORS"). The initial BRIDGETECH Newco1 Directors shall be
                  HERBERT WONG and THOMAS C. KUHN III. The initial AMCARE Newco1
                  Director shall be MOHAN CHELLAPPA. The Party entitled to
                  appoint a director shall have the power to remove such
                  director, and any vacant directorship on the Board shall be
                  filled by a person nominated by the Party entitled to appoint
                  such director. BRIDGETECH and AMCARE shall each vote their
                  shares of Newco1 common stock in favor of the director
                  nominees of the other Party.

                  (ii) Newco2 will be managed by a board of directors (the
                  "NEWCO2 BOARD"). The Newco2 Board will consist of three
                  members of whom two members will be appointed by AMCARE (the
                  "AMCARE NEWCO2 DIRECTORS") and one member will be appointed by
                  BRIDGETECH (the "BRIDGETECH NEWCO2 DIRECTOR"; the AMCARE
                  Newco2 Directors and the BRIDGETECH Newco2 Director are
                  referred to collectively as the "NEWCO2 DIRECTORS"). The
                  initial AMCARE Newco2 Directors shall be MOHAN CHELLAPPA and
                  another person to be designated by Amcare. The initial
                  BRIDGETECH Newco2 Director shall be HERBERT WONG. The Party
                  entitled to appoint a director shall have the power to remove
                  such director, and any vacant directorship on the Board shall
                  be filled by a person nominated by the Party entitled to
                  appoint such director. BRIDGETECH and AMCARE shall each vote
                  their shares of Newco2 common stock in favor of the director
                  nominees of the other Party.

            (b)   Voting Rights of Directors. Each Newco1 Director and Newco2
                  Director will have one vote on all matters requiring the
                  approval or action of the Newco1 Board or the Newco2 Board,
                  respectively.

            (c)   Majority Vote; Supermajority Requirements. Any action or
                  consent of the Board will require the approval of a majority
                  of the Board. In addition, the following actions will require
                  the approval of both AMCARE and BRIDGETECH:

                  (i)   Adopting or effecting any plan of sale, merger,
                        consolidation, dissolution or recapitalization of Newco1
                        or Newco2, as applicable;

                  (ii)  Offering for sale or selling all or substantially all of
                        the assets of Newco1 or Newco2, as applicable;

                  (iii) Directly or indirectly issuing, selling or delivering
                        any equity interest in Newco1 or Newco2, as applicable;

                  (iv)  Effecting any dividend or other distribution of cash or
                        property to any stockholder of Newco1 or Newco2, as
                        applicable;

                  (v)   Amending or restating the Certificate of Incorporation,
                        bylaws or other documents governing the formation and
                        organization of Newco1 or Newco2, as applicable,
                        including without limitation the Newco1 Stockholders
                        Agreement and the Newco2 Stockholders Agreement;

                  (vi)  Purchasing, leasing or otherwise acquiring any asset or
                        group of assets, in an aggregate amount of consideration
                        in excess of $50,000, or purchasing or otherwise
                        acquiring any direct or indirect equity interest in

                                       5

<PAGE>

                            any other entity, or all or substantially all of the
                            assets of any other person or entity;

                     (vii)  Engaging in any transaction or series of transaction
                            with any affiliate of any Party involving
                            consideration in excess of $50,000, other than the
                            transactions specifically contemplated by the
                            Management Agreements or the Stockholders
                            Agreements;

                     (viii) Creating or incurring indebtedness in an aggregate
                            amount in excess of $50,000;

                     (ix)   Material revisions to the Business Plan or Operating
                            Budget of Newco1 or Newco2, as applicable;

                     (x)    Increasing the size of the Newco1 Board or the
                            Newco2 Board under any circumstances; or,

                     (xi)   Commencing a voluntary bankruptcy case, or any
                            similar action.

              (d)    Quorum. A quorum for any meeting of the Board will consist
                     of a majority of the Board and shall include a director
                     designated by each Party.

              (e)    Officers.

                     (i)    The officers of Newco1 shall be appointed by the
                            Newco1 Board and will include a President and a
                            Secretary, as set forth in the Newco1 Bylaws.

                     (ii)   The officers of Newco2 shall be appointed by the
                            Newco2 Board and will include a President and a
                            Secretary, as set forth in the Newco2 Bylaws.

              (f)    Additional Provisions. The Charter Documents of Newco1, the
                     Charter Documents of Newco2, the Newco1 Management
                     Agreement and the Newco2 Management Agreement will contain
                     additional provisions with respect to the management of
                     Newco1 and Newco2, respectively, and related matters that
                     are consistent with this Agreement as the Parties may
                     agree.

       3.4    Capitalization. Neither Party will be permitted or required to
              make any contributions to Newco1 or Newco2 except in accordance
              with the following provisions:

              (a)    Total Initial Capitalization. The Parties acknowledge and
                     agree that the initial capitalization of Newco1 shall be
                     Thirty Thousand Dollars ($30,000) (the "INITIAL
                     CONTRIBUTION"). This amount shall be contributed by
                     BRIDGETECH on or shortly after May 10, 2005. This initial
                     capitalization has been mutually agreed upon by the
                     Parties.

              (b)    Subsequent Bridgetech Investment. BRIDGETECH hereby agrees
                     to contribute an additional Seventy Thousand Dollars
                     ($70,000) to Newco1.

              (c)    Capitalization. If the Parties agree that either Newco1 or
                     Newco2 requires additional capitalization, they will
                     consult with each other for the purpose of

                                       6

<PAGE>

                  agreeing on the amount of additional capital needed, the
                  appropriate portions that should be represented by debt and
                  equity and whether such additional capital will be provided by
                  the Parties or a third party.

            (d)   Other Provisions. The Newco1 Charter Documents and the Newco2
                  Charter Documents will contain such additional provisions with
                  respect to the capitalization of Newco1 and Newco2 and the
                  distribution of income and related matters that are consistent
                  with this Agreement as the Parties may agree.

      3.5   Operations and Accounting Matters.

            (a)   Newco1 will be responsible for the operation of a CRO in the
                  Territory, and Newco2 will be responsible for the operation of
                  MTFs in the Territory, and each will be responsible for the
                  conduct of any Additional Business undertaken by them at the
                  direction of BRIDGETECH and AMCARE in compliance with
                  applicable law and contractual obligations.

                  (i)   Operational control of all activities of Newco1 and
                        Newco2 will be exercised by its management and not by
                        its stockholders; provided, however, that Newco1 and
                        Newco2 shall assign management functions to AMCARE, or
                        otherwise seek managerial advice from Amcare, to the
                        extent agreed by AMCARE, BRIDGETECH and Newco1 and Newco
                        2, under separate management agreements (the "NEWCO1
                        MANAGEMENT AGREEMENT" and the "NEWCO2 MANAGEMENT
                        AGREEMENT").

                  (ii)  The name of Newco1 shall be "Bridgetech CRO, Inc."

                  (iii) The name of Newco2 shall be "AmcareLabs China, Inc."

                  (iv)  The Parties shall cause the Newco1 Board and the Newco2
                        Board to cause Newco1 and Newco2 comply with any legal
                        requirements applicable to Newco1 and Newco2,
                        respectively, under the laws, rules and regulations
                        applicable in the Territory or the United States.

            (b)   BRIDGETECH, AMCARE and Newco 1 shall be entitled to advertise,
                  publicize and otherwise represent to third parties the fact
                  that Newco1 is managed by AMCARE, which is affiliated with
                  Johns Hopkins International Medical Laboratories, in any
                  correspondence, communications (verbal, printed or otherwise),
                  promotional and marketing materials or otherwise. To the
                  extent necessary to accomplish the foregoing provisions,
                  AMCARE will license or sublicense any relevant intellectual
                  property rights to BRIDGETECH and Newco1.

            (c)   BRIDGETECH, AMCARE and Newco2 shall be entitled to advertise,
                  publicize and otherwise represent to third parties the fact
                  that AMCARE is affiliated with Johns Hopkins International
                  Medical Laboratories in any correspondence, communications
                  (verbal, printed or otherwise), promotional and marketing
                  materials or otherwise. To the extent necessary to accomplish
                  the foregoing intent of the parties, AMCARE will license or
                  sublicense any relevant intellectual property rights to
                  BRIDGETECH and Newco2.

            (d)   The fiscal years of Newco1 and Newco2 shall end on December
                  31.

                                       7

<PAGE>

            (e)   Newco's financial accounts will be maintained in accordance
                  with US generally accepted accounting principles. Each Party
                  will be entitled to require Newco1 and Newco2 to provide to it
                  all such information as may be required for the purposes of
                  the preparation of their respective accounts in accordance
                  with such generally accepted accounting principles and the
                  requirements of the law applicable in their respective
                  jurisdictions. Each Party will be entitled to receive all such
                  information relating to the affairs of Newco1 and Newco2 as
                  may be requested at any time and from time to time by any
                  Party. Newco1 and Newco2 will provide to the Parties regular
                  and periodic reports on the business, operations and financial
                  and other affairs of Newco1 and Newco2.

            (f)   Newco1 and Newco2 shall each keep their funds separate from
                  those of any other person and shall maintain its own
                  depository, banking and similar accounts.

            (g)   Any transactions or agreements between Newco1 or Newco2 and
                  any of their affiliates, including BRIDGETECH and AMCARE, will
                  be entered into on an arms'-length basis upon terms that are
                  (i) no less favorable to Newco1 or Newco2, respectively, than
                  would apply in a transaction with a person that is not an
                  affiliate, or (ii) subject to Section 3.3(e)(vii), fully
                  disclosed to and approved by the Board.

            (h)   BRIDGETECH and AMCARE shall cooperate with one another to
                  develop business plans and operating budgets for Newco1 and
                  Newco2 by June 15, 2005.

      3.6   Compliance with Laws Regarding Payments. None of Newco1, Newco2 or
            any of their officers and directors, nor anyone for whose acts or
            defaults they may be vicariously liable or anyone acting on behalf
            of any of them, including any Party hereto, shall make any payments
            in violation of applicable law in connection with or in any way
            relating to or affecting this Agreement or the business to be
            carried on by Newco1 or Newco2, nor shall such persons make any
            payments in violation of any applicable code of conduct of either
            BRIDGETECH or AMCARE, provided that such code of conduct is
            commercially reasonable. The Parties acknowledge that the laws of
            the United States of America, including the Foreign Corrupt
            Practices Act, prohibit any direct or indirect payment of money or
            anything of value to any governmental official, international
            organization, political Party or candidate for political office for
            the purpose of obtaining or retaining business. The Parties
            represent and warrant to each other that in the performance of their
            obligations under this Agreement or otherwise in connection with
            this Agreement they have not made and agree that they will not make
            any such prohibited payment.

4.    Restrictions on the Activities of BRIDGETECH and AMCARE. The Parties will
      be subject to the following provisions with respect to the activities of
      Newco1 and Newco2:

      4.1 Exclusive Dealings in the Territory. Except to the extent prohibited
      by applicable law, rules and regulations:

            (a)   Within the Territory, Newco1 shall be the exclusive provider
                  of CRO services to BRIDGETECH, AMCARE and their Affiliates
                  during the Project Term.

            (b)   Within the Territory, Newco2 shall be the exclusive provider
                  of clinical diagnostic anatomic and clinical pathology
                  laboratory services to BRIDGETECH, AMCARE and their Affiliates
                  during the Project Term.

                                       8

<PAGE>

      4.2   Restrictions.

            (a)   In furtherance of the foregoing, during the term of this
                  Agreement, BRIDGETECH and AMCARE, will not, except in
                  situations to which the exclusivity provisions in Section 4.1
                  above do not apply because of applicable law, rules or
                  regulations:

                  (i)   establish or operate, directly or indirectly, a
                        pathology lab or clinical research organization in the
                        Territory, other than through Newco1 and Newco2;

                  (ii)  own any interest in, directly or indirectly, or
                        otherwise participate in, directly or indirectly, any
                        entity other than Newco1 or Newco2 that is involved in
                        any aspect of either a MTF or clinical research
                        organization in the Territory, or

                  (iii) compete, directly or indirectly, in the Territory in any
                        other activity undertaken by Newco1 or Newco2 in the
                        Territory.

      4.3 Definitions. For purposes of this Section 4, the term "AFFILIATE"
means, for any person, any stockholder, partner, member or other equity owner of
such person or any other person directly or indirectly controlling, controlled
by or under common control with such person.

5.    Term and Termination.

      5.1   Term. Subject to Sections 5.3, the Project will have an initial term
            of 10 years (the "PROJECT TERM"), at the end of which time the
            Project Term may be extended for additional 1 year terms (all such
            renewal terms shall be considered part of the "Project Term"),
            unless either Party notifies the other no later than 60 days before
            the end of the Project Term that it does not wish to extend the
            Project Term.

      5.2   End of Project Term. Unless the Project Term is terminated
            previously pursuant to Section 5.3, at the end of the Project Term,
            the Parties will enter into negotiations with each other for the
            purpose of determining a price at which either Party would purchase
            the other Party's shares in Newco1 and/or Newco2. Unless otherwise
            agreed the purchase price will be payable in cash at closing. If the
            Parties are unable to agree upon a price for either or both of
            Newco1 and Newco2, then the Parties will jointly retain, or cause
            Newco1 and Newco2, as applicable, to retain, an internationally
            recognized investment bank or other financial advisor to solicit a
            purchaser or purchasers for all the outstanding shares of Newco1
            and/or Newco2, together or separately, each as a going concern with
            all outstanding contracts, including those to which BRIDGETECH,
            AMCARE or their affiliates are a Party, other than any outstanding
            indebtedness of Newco1 and Newco2 to the Parties which will be
            repaid upon sale. In the event that no bids are received within 180
            days after the end of the Project Term for Newco1 or Newco2,
            respectively, or if for any reason a proposed sale to a successful
            bidder does not occur within 180 days after the end of the Project
            Term, then the Parties will require that Newco1 and Newco2
            (whichever receives no bids or remains unsold at the end of the
            prescribed periods) be wound up in accordance with applicable law.
            From the end of the Project Term until such time as Newco1 and
            Newco2 are sold or wound up as provided above, this Agreement and
            the Related Agreements shall remain in effect, and Newco1 and Newco2
            shall be operated in the ordinary course of business.

                                       9

<PAGE>

      5.3   Termination upon default. A Party (the "NON-DEFAULTING PARTY") will
            have the right to terminate this Agreement and the Related
            Agreements (with respect to either or both of Newco1 and Newco2) by
            notice (a "DEFAULT NOTICE") to the other Party (the "DEFAULTING
            PARTY") upon the occurrence of an Event of Default with respect to
            the other Party if such Event of Default is not cured by the
            Defaulting Party within 60 days following receipt of the Default
            Notice.

            (a)   "EVENT OF DEFAULT" means with respect to a Party:

                  (i)   a material breach by the Defaulting Party of the
                        representations, warranties, covenants, or obligations
                        of such Party under any of the Project Documents, or any
                        other agreements between such Party and the
                        Non-Defaulting Party or such Party and Newco1 or Newco2.

                  (ii)  The repudiation by that Party or its guarantor of its
                        obligations with respect to any performance not yet due:
                        (A) under this Agreement; or (B) under any Related
                        Agreement.

                  (iii) That Party or its guarantor experiences an Insolvency
                        Event.

                  (iv)  The making by that Party or its guarantor of a
                        materially incorrect or misleading representation or
                        warranty under this Agreement or any Related Agreement.

            (b)   "INSOLVENCY EVENT" with respect to a Party means that either
                  that Party or its guarantor:

                  (i)   is dissolved (other than pursuant to a consolidation,
                        amalgamation or merger);

                  (ii)  becomes insolvent or is unable to pay its debts or
                        fails, or admits in writing its inability generally, to
                        pay its debts as they become due;

                  (iii) makes a general assignment, arrangement or composition
                        with or for the benefit of its creditors;

                  (iv)  institutes or has instituted against it a proceeding
                        seeking a judgment of insolvency or bankruptcy or any
                        other relief under any bankruptcy or insolvency law or
                        other similar law affecting creditors' rights, or a
                        petition is presented for its winding-up or liquidation;

                  (v)   has a resolution passed for its winding-up, official
                        management or liquidation (other than pursuant to a
                        consolidation, amalgamation or merger);

                  (vi)  seeks or becomes subject to the appointment of an
                        administrator, provisional liquidator, conservator,
                        receiver, trustee, custodian or other similar official
                        for it or for all or substantially all its assets;

                  (vii) has a receiver appointed to take possession of all or
                        substantially all its assets or has a distress,
                        execution, attachment, sequestration or other legal
                        process levied, enforced or sued on or against all or
                        substantially all its assets;

                                       10

<PAGE>

                     (viii) causes or is subject to any event with respect to it
                            which, under the applicable laws of any
                            jurisdiction, has an analogous effect to any of the
                            events specified in clauses (i) to (vii)
                            (inclusive); or

                     (ix)   takes any action in furtherance of, or indicating
                            its consent to, approval of, or acquiescence in, any
                            of the foregoing acts.

       5.4    Remedies upon default. Upon a termination pursuant to Section 5.3,
              the Non-Defaulting Party will have the right to exercise any one
              or more of the following remedies:

              (a)    The Non-Defaulting Party shall have the right to purchase
                     from the Defaulting Party all of the shares of either or
                     both of Newco1 and Newco2 owned by the Defaulting Party
                     (including any shares held by its assignees), at a price
                     equal to

                     (i)    the Ownership Percentage of the Defaulting Party,
                            multiplied by

                     (ii)   the fair market value of the assets of Newco1 and/or
                            Newco2 after taking into account all liabilities of
                            Newco1 and/or Newco2 as determined by an
                            internationally recognized investment bank or other
                            financial advisor.

              (b)    The Non-Defaulting Party shall have the right to require
                     the Defaulting Party to purchase all shares in Newco1
                     and/or Newco2 held by the Non-Defaulting Party at a price
                     equal to

                     (i)    the Ownership Percentage of the Non-Defaulting
                            Party, multiplied by

                     (ii)   the fair market value of the assets of Newco1 and/or
                            Newco2 after taking into account all liabilities of
                            Newco1 and/or Newco2 as determined by an
                            internationally recognized investment bank or other
                            financial advisor.

              (c)    The Non-Defaulting Party shall have the right to require
                     the Parties to bid against each other to purchase the
                     outstanding shares in Newco1 and/or Newco2 held by the
                     other Party, or if no such bids are received, to require
                     Newco1 or Newco2 to be wound up in accordance with
                     applicable law.

              (d)    The Non-Defaulting Party shall have the right to recover
                     from the Defaulting Party damages arising from such Event
                     of Default pursuant to Section 10 hereof.

       5.5    Non-Defaulting Party Right to Cure. Upon an Event of Default under
              Section 5.3(a), the Non-Defaulting Party may, at any time prior to
              giving a Default Notice, cure such Event of Default, and recover
              from the Defaulting Party the costs of such cure.

       5.6    Winding Up. If either Newco1 or Newco2 is required to be wound up
              then, unless otherwise agreed and subject to applicable law,

              (a)    all outstanding liabilities of Newco1 or Newco2, as
                     applicable, will be paid in full or, if appropriate,
                     covered by adequate reserves set aside for such payment,

              (b)    all accrued and unpaid dividends or other distributions
                     will be paid,

              (c)    any remaining assets will (A) be distributed to the
                     stockholders in accordance with their Ownership Percentages
                     or (B) if such distribution is not practicable,

                                       11

<PAGE>

                     will be sold at fair market value with the proceeds being
                     distributed to the stockholders in accordance with their
                     Ownership Percentages.

6.     Representations and Warranties.

       6.1    Representations and warranties of BRIDGETECH. BRIDGETECH hereby
              represents and warrants to AMCARE as follows:

              (a)    Status. BRIDGETECH is a corporation validly existing and in
                     good standing under the laws of the State of Delaware,
                     U.S.A. BRIDGETECH has all necessary power to enter into
                     this Agreement.

              (b)    Authorization, etc. The execution, delivery and performance
                     by BRIDGETECH of this Agreement has been authorized by all
                     necessary action on the part of such entity and its
                     stockholders, as the case may be, and does not and will not

                     (i)    violate the organizational documents of BRIDGETECH
                            or any applicable law, or

                     (ii)   contravene, conflict with, or result in a default
                            under any order or judgment of any court or other
                            governmental authority or any agreement to which
                            BRIDGETECH is a Party or by which any of its assets
                            may be bound.

              (c)    Governmental and Other Consents etc. Except as set forth in
                     Schedule 6.1(c), all governmental and other authorizations,
                     approvals, consents, notices, and filings, including any
                     approvals, consents or notices under contracts to which
                     BRIDGETECH is a Party, that are required to have been
                     obtained or submitted by BRIDGETECH prior to the execution
                     and delivery of this Agreement by BRIDGETECH have been
                     obtained and are in full force and effect. BRIDGETECH is
                     not aware of any reason why any other such authorizations,
                     approvals, consents, notices or filings that may be
                     required on the part of BRIDGETECH (or any other affiliate
                     that is or will be involved in this Project) in connection
                     with the Project will not be obtained in a timely manner
                     without the imposition of any conditions that would
                     adversely affect the ability of BRIDGETECH or any such
                     affiliate to participate in the Project as contemplated by
                     this Agreement.

              (d)    Enforceability. Its obligations and the obligations of
                     BRIDGETECH and any affiliate under this Agreement and any
                     other agreement entered into by such entity in connection
                     with this Agreement or the Project are and will be the
                     legal, valid, and binding obligation of BRIDGETECH or such
                     affiliate as the case may be, enforceable against such
                     entity in accordance with its terms, subject to applicable
                     bankruptcy, reorganization, insolvency, moratorium, or
                     similar laws affecting creditors' rights generally and
                     subject as to enforceability, to equitable principle of
                     general application regardless of whether enforcement is
                     sought in a proceeding in equity or at law.

              (e)    Litigation. There are no suits, proceedings, judgments,
                     rulings or orders by or before any governmental authority,
                     court or arbitrator or any pending or threatened action or
                     proceeding affecting BRIDGETECH or any of their affiliates
                     before any governmental authority, court or arbitrator that
                     could reasonably be expected to materially and adversely
                     affect the financial condition or operations

                                       12

<PAGE>

                     of BRIDGETECH or the ability of BRIDGETECH and its
                     affiliates to perform their respective obligations under
                     this Agreement or any other agreement entered into by such
                     entity in connection with this Agreement or the Project, or
                     which purports to affect the legality, validity or
                     enforceability of this Agreement or any other such
                     agreement.

       6.2    Representations and warranties of AMCARE. AMCARE hereby represents
              and warrants to BRIDGETECH as follows:

              (a)    Status. AMCARE is a corporation duly organized, validly
                     existing and in good standing under the laws of the State
                     of Delaware, U.S.A. AMCARE has all necessary power to enter
                     into this Agreement.

              (b)    Authorization, etc. The execution, delivery and performance
                     by AMCARE of this Agreement has been authorized by all
                     necessary action on the part of such entity and its
                     stockholders and does not and will not

                     (i)    violate the organizational documents of AMCARE or
                            any applicable law, or

                     (ii)   contravene, conflict with, or result in a default
                            under any order or judgment of any court or other
                            governmental authority or any agreement to which
                            AMCARE is a Party or by which any of its assets may
                            be bound.

              (c)    Governmental and Other Consents etc. Except as set forth on
                     Schedule 6.2(c), all governmental and other authorizations,
                     approvals, consents, notices, and filings, including any
                     approvals, consents or notices under contracts to which
                     AMCARE is a Party, that are required to have been obtained
                     or submitted by AMCARE prior to the execution and delivery
                     of this Agreement by AMCARE have been obtained and are in
                     full force and effect. AMCARE is not aware of any reason
                     why any other such authorizations, approvals consents,
                     notices or filings that may be required on the part of
                     AMCARE (or any other affiliate that is or will be involved
                     in this Project) in connection with the Project will not be
                     obtained in a timely manner without the imposition of any
                     conditions that would adversely affect the ability of
                     AMCARE or any such affiliate to participate in the Project
                     as contemplated by this Agreement.

              (d)    Affiliate Status. AMCARE is party to a written agreement
                     with Johns Hopkins International Medical Laboratories
                     pursuant to which AMCARE is designated as an "affiliate" of
                     Johns Hopkins International Medical Laboratories. Such
                     agreement is a legal, valid and binding obligation with
                     respect to each of AMCARE and Johns Hopkins International
                     Medical Laboratories. Neither Johns Hopkins Medical
                     Laboratories nor AMCARE is in breach of or in default under
                     such agreement. During the Project Term, AMCARE shall
                     notify BRIDGETECH in writing immediately upon the
                     termination or expiration of such agreement or any
                     amendment thereof or default thereunder that results or
                     could reasonably be expected to result in AMCARE no longer
                     being an affiliate of Johns Hopkins International Medical
                     Laboratories.

              (e)    Enforceability. Its obligations and the obligations of
                     AMCARE and any affiliate under this Agreement and any other
                     agreement entered into by such entity in connection with
                     this Agreement or the Project are and will be the legal,
                     valid, and

                                       13

<PAGE>

                     binding obligation of AMCARE or such affiliate enforceable
                     against such entity in accordance with its terms, subject
                     to applicable bankruptcy, reorganization, insolvency,
                     moratorium, or similar laws affecting creditors' rights
                     generally and subject as to enforceability, to equitable
                     principle of general application regardless of whether
                     enforcement is sought in a proceeding in equity or at law.

              (f)    Litigation. There are no suits, proceedings, judgments,
                     rulings or orders by or before any governmental authority,
                     court or arbitrator or any pending or threatened action or
                     proceeding affecting AMCARE before any governmental
                     authority, court or arbitrator that could reasonably be
                     expected to materially and adversely affect the financial
                     condition or operations of AMCARE or the ability of AMCARE
                     to perform its obligations under this Agreement or any
                     other agreement entered into by such entity in connection
                     with this Agreement or the Project, or which purports to
                     affect the legality, validity or enforceability of this
                     Agreement or any other such Agreement.

       6.3    No other representations or warranties. Except for the
              representations and warranties expressly set forth in this
              Agreement neither Party is relying upon any statement,
              representation or warranty made by the other Party or any of the
              other Party's affiliates or agents, or any of their respective
              officers or employees. Without limiting the preceding sentence,
              each Party expressly acknowledges, represents and warrants to the
              other Party as follows:

              (a)    The Project. No representation or warranty is made by the
                     other Party or any of its affiliates with respect to the
                     possible revenues, profits or losses that may arise from
                     the Project or any transaction contemplated by this
                     Agreement, any Related Agreement or any other Project
                     Documents.

              (b)    Investment Risk.

                     (i)    The investments in Newco1, Newco2 and the Project
                            contemplated by this Agreement involve a high degree
                            of risk and are illiquid.

                     (ii)   Neither of the Parties is under any obligation to
                            register any shares or other equity interests in
                            Newco1 or Newco2 with the applicable regulatory
                            bodies of the Territory, the U.S. Securities and
                            Exchange Commission or any other federal, state or
                            provincial governmental agencies of the Territory or
                            the U.S., or to take any other action necessary in
                            order to make compliance with an exemption from
                            registration available, or to otherwise offer the
                            common shares of Newco1 or Newco2 publicly.

                     (iii)  Each Party has a full understanding of the terms and
                            risks of the Project and is capable of assuming
                            those risks.

              (c)    Information. Representatives of each Party have had an
                     opportunity to ask questions and receive answers about the
                     Project and to obtain additional information for
                     verification purposes. Each such Party has retained and
                     will retain legal and professional advisors of its choice
                     and is not relying upon advice rendered by any advisors
                     employed or retained by the other Party.

              (d)    Relationship between the Parties; Non-Reliance. In entering
                     into this Agreement and any Related Agreement and any
                     transactions in connection with the Project,

                                       14

<PAGE>

                  (i)   it is acting for its own account as a principal (and not
                        as an adviser, agent, broker or in any other capacity,
                        fiduciary or otherwise),

                  (ii)  it has made its independent decision to pursue the
                        Project and to enter into the Project Documents based on
                        its own evaluation of the costs, risks and benefits of
                        the Project and not in reliance upon any view expressed
                        by any other Party to this Agreement or its affiliates,

7.    Guarantees. Unless otherwise agreed by each Party, neither BRIDGETECH nor
      AMCARE will be required to provide any guarantee either to each other or
      to any third party with respect to the obligations of Newco1 or Newco2
      under any loan or credit agreement, lease, purchase or supply agreement or
      other agreement of any kind.

8.    Confidentiality and Intellectual Property.

      8.1   Confidential Information. For purposes of this Agreement, subject to
            the special provisions in Section 8.3 below, "CONFIDENTIAL
            INFORMATION" means information provided by a Party to this Agreement
            (the "DISCLOSING PARTY") to any other Party to this Agreement or to
            Newco1 or Newco2 (the "RESTRICTED PARTY") in connection with the
            transactions and relationships contemplated by the Project
            Documents, including but not limited to:

            (a)   any data or information that is competitively sensitive
                  material, and not generally known to the public, including,
                  but not limited to, products, planning information, marketing
                  strategies, plans, finance operations, sales estimates,
                  business plans, and internal performance results relating to
                  the past, present or future business activities of the
                  Disclosing Party and its affiliates and, services and products
                  provided to or obtained from, the terms of related contracts
                  with, and the identities of any other identifying information
                  regarding the customers, clients and suppliers of the
                  Disclosing Party or its affiliates;

            (b)   any scientific or technical information, design, process,
                  procedure, formula, or improvement that is commercially
                  valuable and secret in the sense that its confidentiality
                  affords the Disclosing Party a competitive advantage over its
                  competitors;

            (c)   all confidential or proprietary concepts, documentation,
                  reports, data (including magnetic tapes), specifications, web
                  sites, screen formats, computer software, source code, object
                  code, flow charts, databases, inventions, systems, system
                  security features, system enhancements, information, know-how,
                  show-how and trade secrets, whether or not patentable or
                  copyrightable;

            (d)   all documents, inventions, substances, engineering and
                  laboratory notebooks, drawings, diagrams, specifications,
                  bills of material, equipment, prototypes and models, and any
                  other tangible manifestation of the foregoing;

            (e)   any other information that a Disclosing Party treats as
                  confidential information provided by an affiliate or other
                  third party; and

            (f)   any information derived from any of the foregoing that is
                  treated as confidential.

                                       15

<PAGE>

      8.2   Nondisclosure. Each Party shall treat as confidential, and the
            Parties shall together cause Newco1 and Newco2 to treat as
            confidential, all Confidential Information of the other Party, shall
            not use such Confidential Information except as set forth herein,
            and shall use reasonable efforts not to disclose such Confidential
            Information to any third party. Without limiting the foregoing, each
            of the Parties shall use at least the same degree of care which it
            uses to prevent the disclosure of its own confidential information
            of like importance to prevent the disclosure of Confidential
            Information disclosed to it by the other Party under this Agreement.
            Neither BRIDGETECH nor AMCARE shall be entitled to access, use or
            disclose any Confidential Information of the other Party solely by
            virtue of the provision of such Confidential Information by the
            Disclosing Party to Newco1 or Newco2.

      8.3   Exceptions. Notwithstanding the above, neither Party shall have
            liability to the other with regard to any Confidential Information
            of the other which the Restricted Party can prove: (i) was in the
            public domain at the time it was disclosed or has entered the public
            domain through no fault of the Restricted Party; (ii) was known to
            the Restricted Party, without restriction, at the time of disclosure
            (iii) is disclosed with the prior written approval of the Disclosing
            Party; (iv) was independently developed by the Restricted Party
            without any use of the Confidential Information of the other Party,
            (v) becomes known to the Restricted Party, without restriction, from
            a source other than the Disclosing Party without breach of this
            Agreement by the Restricted Party and otherwise not in violation of
            the Disclosing Party's rights; (vi) is disclosed generally to third
            parties by the Disclosing Party without restrictions similar to
            those contained in this Agreement; or (vii) is disclosed pursuant to
            the order or requirement of a court, administrative agency, or other
            governmental body; provided, however, that the Restricted Party
            shall provide prompt notice thereof to the Disclosing Party to
            enable the Disclosing Party to seek a protective order or otherwise
            prevent or restrict such disclosure.

      8.4   Return of Confidential Information. Upon expiration or termination
            of the Project, each Party shall return or destroy, and together
            shall cause Newco1 and/or Newco2, as applicable, to return or
            destroy, all Confidential Information received from the other Party.

      8.5   Confidentiality of Agreement. Each Party shall be entitled to
            disclose the existence of this Agreement, but agrees that the terms
            and conditions of this Agreement shall be treated as Confidential
            Information and shall not be disclosed to any third party; provided,
            however, that each Party may disclose the terms and conditions of
            this Agreement: (i) as required by any court or other governmental
            body; (ii) as otherwise required by law; (iii) to legal counsel of
            the Parties; (iv) in confidence, to accountants, banks, and
            financing sources and their advisors; (v) in connection with the
            enforcement of this Agreement or rights under this Agreement; (vi)
            in confidence, in connection with an actual or proposed merger,
            acquisition, or similar transaction or (vii) in accordance with
            Section 9, below.

      8.6   Intellectual Property. Each of BRIDGETECH and AMCARE acknowledge
            that, during the course of the Project, BRIDGETECH or AMCARE may
            license or otherwise permit Newco1 or Newco2 to use certain patents,
            trademarks, trade names, service marks, domain names, copyrights,
            designs, processes, formulae, methods, schematics, technology,
            invention, trade secrets, know-how, computer software programs or
            applications and tangible or intangible proprietary information or
            material (collectively, "INTELLECTUAL PROPERTY") owned or licensed
            by such Party (the "OWNER") in order to permit Newco1 and Newco2 to
            perform their obligations under the Project Documents or otherwise.
            The Parties acknowledge and agree that, and the Parties shall cause
            Newco1

                                       16

<PAGE>

            and Newco2 to acknowledge and agree that, except to the extent that
            (i) such Intellectual Property is expressly and specifically
            contributed in writing by the Owner thereof as part of an equity
            contribution to Newco1 or Newco2 to which the other Party consents
            in writing, or (ii) such Intellectual Property is expressly and
            specifically sold to Newco1 or Newco2 by the Owner thereof in
            accordance with the provisions of this Agreement, none of Newco1,
            Newco2 or the non-Owner Party shall acquire any rights, express or
            implied, in the Intellectual Property other than those specified in
            Project Document pursuant to which such license or right to use was
            granted. For the avoidance of doubt, in no event shall Newco1 or
            Newco2 license or otherwise permit the non-Owner Party or any third
            party to use any such Intellectual Property to which it may be given
            access pursuant to the terms of the Project Documents without the
            prior written consent of the Owner.

      8.7   Remedies. Any breach of the restrictions contained in this Section 8
            is a breach of this Agreement which may cause irreparable harm to
            the non-breaching Party. Any such breach shall entitle the
            non-breaching Party to injunctive relief in addition to all legal
            remedies.

9.    Press Release and Announcements. BRIDGETECH and AMCARE agree that no
      public release or announcement concerning the transactions contemplated
      hereby shall be issued or made by or on behalf of any Party without the
      prior consent of the other Party, except that either Party may, after
      consultation with counsel, make announcements that such Party reasonably
      may determine are necessary to comply with applicable law. AMCARE
      acknowledges and agrees that BRIDGETECH may be required to announce the
      terms of this Agreement and make publicly available this Agreement and
      that no breach of this Section 9 shall be deemed to result therefrom.
      Notwithstanding the foregoing, BRIDGETECH and AMCARE shall cooperate to
      prepare a joint press release to be issued in connection with the Closing.

10.   Indemnification.

      10.1  Indemnification. Each Party (the "Indemnifying Party") will defend,
            indemnify, and hold the other Party and its Affiliates, officers and
            directors, shareholders, and each of its and their successors and
            permitted assigns (the "Indemnified Parties"), harmless from and
            against any and all liabilities, judgments, losses, actual damages,
            costs, and expenses (including without limitation reasonable
            attorneys' and experts' fees) which any or all of them may hereafter
            incur themselves or pay out to another by reason of any claim, suit,
            or proceeding brought by a third party, at law or in equity, that
            arises out of or relates to (i) a material breach of any
            representation, warranty, covenant, obligation or other provision of
            this Agreement by the Indemnifying Party or (ii) any other Event of
            Default, except to the extent caused by the gross negligence or
            willful misconduct of an Indemnified Party.

      10.2  Indemnification Procedures. To the extent that the indemnification
            described in Section 10.1 above relates to a claim, suit or
            proceeding by a third party, the Indemnifying Party must keep the
            Indemnified Parties fully informed regarding the status or progress
            of any claim, suit, settlement or proceeding related hereto. The
            defense of the Indemnified Parties shall be provided by attorneys
            selected and retained by the Indemnifying Party at its sole cost and
            expense, which attorneys shall be subject to the prior written
            approval of the Indemnified Parties (not to be unreasonably
            withheld, conditioned or delayed). The Indemnified Parties shall
            have the right to participate, and be represented by attorneys or
            other representatives of their choosing (at their sole cost and
            expense) in the defense of such claim, suit or proceeding and all
            settlement negotiations relative thereto. The Indemnifying Party
            shall have the right to determine all matters in connection with the
            claim, suit or proceeding including, without limitation, in
            connection with negotiations relating to the settlement thereof,
            provided, however, that any settlement of such claim,

                                       17

<PAGE>

            suit or proceeding shall require the Indemnified Parties to be
            released of all liability with respect thereto. In the event that
            the Indemnifying Party fails or refuses to indemnify any Party with
            respect to any claim or matter indemnified under this Section 10
            after written notice and a reasonable opportunity to do so, said
            Indemnified Party shall have the right to defend such claim or
            matter at the sole cost and expense of the Indemnifying Party,
            through attorneys selected by the Indemnified Party in its sole
            discretion. The indemnities set forth in this Section 10 shall
            survive expiration or earlier termination of this Agreement.

      10.3  Exclusion of Consequential Damages. NOTWITHSTANDING ANYTHING TO THE
            CONTRARY CONTAINED IN THIS AGREEMENT, NEITHER PARTY SHALL, UNDER ANY
            CIRCUMSTANCES, BE LIABLE TO THE OTHER PARTY FOR LOST PROFITS,
            CONSEQUENTIAL, INCIDENTAL, SPECIAL, PUNITIVE, OR INDIRECT DAMAGES
            ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE TRANSACTIONS
            CONTEMPLATED HEREUNDER, EVEN IF THE PARTY HAS BEEN APPRISED OF THE
            LIKELIHOOD OF SUCH DAMAGES.

11.   Dispute Resolution Procedure.

      11.1  General. The Parties desire to resolve disputes arising out of this
            Agreement without litigation. Accordingly, except as otherwise
            provided in this Section 11, all disputes, controversies, or claims
            arising out of or relating to this Agreement or an Event of Default
            (as defined in this Agreement), or the breach, termination, or
            validity of this Agreement (a "Dispute"), shall be resolved in
            accordance with this Section 11.

      11.2  Discussions to Resolve Dispute. At the written request of either
            Party identifying a Dispute, the Parties to the Dispute shall
            appoint knowledgeable, responsible representatives to meet and
            negotiate in good faith to attempt to resolve the Dispute. The
            Parties intend that these negotiations be conducted by non-lawyer,
            business representatives, including at least one senior executive of
            each Party to the dispute. The location, format, frequency,
            duration, and conclusion of these discussions shall be left to the
            discretion of the representatives. Discussion and correspondence
            among the representatives for purposes of these negotiations shall
            be treated as confidential information developed for purposes of
            settlement, exempt from discovery and production, which shall not be
            admissible in any arbitration or other proceeding. Documents
            identified in or provided with such communications, but which were
            not prepared for purposes of the negotiations, are not so exempted.

      11.3  Arbitration. Any Dispute not resolved by negotiation pursuant to
            Section 11.2 within thirty (30) days of the written request for
            negotiation, shall be finally resolved, at the initiative of either
            Party, by binding arbitration in accordance with this Section 11 and
            the International Arbitration Rules of the American Arbitration
            Association (the "AAA Rules").

      11.4  Venue. Any arbitration under this Section 11 shall be conducted
            pursuant to the Federal Arbitration Act, 9 U.S.C. Section 1 et seq.,
            in New York, New York or such other location as may be agreed by the
            Parties.

      11.5  Selection of Arbitrators. There shall be one arbitrator, who shall
            have at least five (5) years' experience in or with the health care
            industry. If the Parties are unable to agree on the selection of the
            arbitrator within twenty-one (21) days of the notice of arbitration,
            the arbitrator shall be chosen in accordance with the AAA Rules.

                                       18

<PAGE>

      11.6  Waiver of Special, Consequential, and Punitive Damages. The award of
            the arbitrator may not include any element of special,
            consequential, or punitive damages, and the right to claim such
            damages is hereby expressly waived by each Party.

      11.7  Provisional Relief. Either Party may seek from any court of
            competent jurisdiction any provisional relief that may be required
            to protect its rights or rights created pursuant to this Agreement,
            without prejudice to its agreement to arbitrate Disputes under this
            Section 11.

      11.8  Jurisdiction. The Parties hereby consent to the non-exclusive
            jurisdiction of the Courts of the State of New York for purposes of
            any application for provisional relief under Section 11.7 or to
            enforce any provision of this Section 11, or any arbitration award
            hereunder, but both Parties remain free to seek similar relief from
            any court in any other jurisdiction in which such relief may be
            needed.

      11.9  Award; Fees and Expenses. The award of the arbitrator may be entered
            in any court of competent jurisdiction. The fees and costs of the
            Parties to any dispute resolved by arbitration under this Section
            11, including without limitation the arbitrator's fees and all
            attorneys' fees and expenses, shall be allocated in the award.

12.   Miscellaneous.

      12.1  Binding Effect. This Agreement shall be binding on and inure to the
            benefit of the Parties and their respective successors and permitted
            assigns.

      12.2  Assignment. This Agreement shall not be assigned by either Party
            without the prior written consent of the other Party, not to be
            unreasonably delayed or withheld, and any purported such assignment
            without such consent shall be void. For purposes of this Section
            12.2, a merger involving a Party shall be deemed to result in an
            assignment of this Agreement to the surviving entity in the merger,
            regardless of whether the Party is the surviving entity or merging
            entity to such merger.

      12.3  Notices And Other Communications.

            (a)   Each notice, communication and delivery under this Agreement
                  (i) shall be made in writing signed by the Party making the
                  same, (ii) shall specify the Section of this Agreement
                  pursuant to which it is given, (iii) shall be given either in
                  person or by telecopier, effective upon such delivery or the
                  confirmed transmission and (iv) if not given in person, shall
                  be sent to the applicable Party at the address set forth below
                  (or at such other address as the applicable Party may furnish
                  to the other Party pursuant to this subsection) by
                  international courier delivery service, effective upon the
                  second business day after such notice is deposited, delivery
                  charges pre-paid, with such international courier delivery
                  service. Each Party's notice information is as follows:

            BRIDGETECH:  Bridgetech Holdings International, Inc.
                         777 S. Highway 101, Suite 215
                         Solana Beach, California 92075
                         USA
                         Attn: Thomas C. Kuhn III
                         Phone: 619-342-7440
                         Fax: 619-342-7497

                                       19

<PAGE>

                         With a copy to:

                         Sutherland Asbill & Brennan LLP
                         999 Peachtree Street, NE
                         Atlanta, Georgia 30309
                         USA
                         Attn: B. Knox Dobbins
                         Phone: 404-853-8053
                         Fax: 404-853-8806

            AMCARE:      AmcareLabs International, Inc
                         5801 Smith Avenue, Suite 305
                         Baltimore, Maryland 21207
                         USA
                         Attn: Mohan Chellappa
                         Phone: 410-735-6558
                         Fax: 410-735-6552

            (b)   Either Party may modify any information specified in this
                  Section 12.3 by giving written notice to the other Party.

            (c)   All written communications made as provided in Section 12.3(a)
                  shall be deemed given upon receipt by the Party to which it is
                  addressed, which, in the case of facsimile, shall be deemed to
                  occur by the close of the business day in the place of receipt
                  on which the same is transmitted or such earlier time as is
                  confirmed by the receiving Party.

      12.4  Severability. If any term or provision of this Agreement, or the
            application thereof to any person or circumstance, shall to any
            extent be contrary to any applicable law or regulation or otherwise
            invalid or unenforceable, the remainder of this Agreement or the
            application of such term or provision to persons or circumstances
            other than those as to which it is contrary, invalid or
            unenforceable shall not be affected thereby and, to the extent
            consistent with the overall intent of this Agreement taken as a
            whole, shall be enforced to the fullest extent permitted by
            applicable law and regulation.

      12.5  Amendment; No Waiver. This Agreement shall only be amended upon the
            written agreement of each Party hereto. No waiver by either Party of
            any one or more defaults by the other Party in the performance of
            any of the provisions of this Agreement shall operate or be
            construed as a waiver of any other default or defaults whether of a
            like kind or different nature. No delay by either Party in the
            enforcement of any of its rights under this Agreement shall be
            deemed to be a waiver of such rights.

      12.6  Relationship between the Parties. Except to the extent contemplated
            by this Agreement, nothing in this Agreement shall create or be
            deemed to create a partnership or joint venture between the Parties
            and except to the extent expressly specified in this Agreement or
            any Related Agreement no Party will or is entitled to act as agent
            for any other Party.

      12.7  Expenses. Each Party will be responsible for the payment of all
            costs and expenses incurred by it in connection with the preparation
            and negotiation of this Agreement and the Related Agreements and
            unless, and only to the extent, agreed by the Parties none of such
            costs or expenses will be borne by Newco1 or Newco2.

                                       20

<PAGE>

      12.8  No Third Party Beneficiaries. This Agreement confers no rights
            whatsoever upon any person other than BRIDGETECH, AMCARE, Newco1 and
            Newco2 and shall not create, or be interpreted as creating, any
            standard of care, duty or liability to any person not a Party
            hereto.

      12.9  Governing Law. The Project Documents will be governed by the laws of
            Delaware except as specifically provided in such documents, without
            regard to principles of conflict of laws.

      12.10 Certain Rules of Construction. The following rules of construction
            will apply throughout this Agreement and any Project Document.

            (a)   Headings. Any headings used in this Agreement or in any other
                  Project Documents are for the purpose of convenience only and
                  shall not affect the meaning or interpretation of the
                  agreement or document in question.

            (b)   Words of Inclusion. The word "including" will not be construed
                  to be a term of limitation, so that references to "included"
                  matters or items will be regarded as illustrative and will not
                  be interpreted as a limitation on, or an exclusive listing of,
                  the matters or items referred to.

            (c)   Singular and Plural Forms; Genders. Whenever the context so
                  requires, the singular includes the plural and the plural
                  includes the singular, and the gender of any pronoun includes
                  the other genders.

      12.11 Counterparts. This Agreement may be executed by each Party upon a
            separate copy, and in several counterparts, each of which will be
            deemed to be an original and all of which, taken together, shall
            constitute one and the same instrument.

                            (Signature page follows.)

                                       21

<PAGE>

IN WITNESS WHEREOF, the Parties have executed this Agreement, or caused it to be
executed by their duly authorized officers or agents all as of the day and year
first above written.

                                       BRIDGETECH  HOLDINGS INTERNATIONAL, INC.

                                       By:    /s/ Herbert Wong
                                              ---------------------------------
                                       Name:  Herbert Wong
                                       Title: Chairman

                                       AMCARE LABS INTERNATIONAL, INC.

                                       By:    /s/ Mohan Chellappa
                                              ---------------------------------
                                       Name:  Mohan Chellappa
                                       Title: President

                                       22

<PAGE>

                                    EXHIBIT A

                      FORM OF CERTIFICATE OF INCORPORATION

See attached.

                                       23

<PAGE>

                          CERTIFICATE OF INCORPORATION

                                       OF

                              BRIDGETECH CRO, INC.

      FIRST: The name of the corporation is "Bridgetech CRO, Inc.".

      SECOND: The address of the registered office of the corporation in the
State of Delaware is The Corporation Trust Company, 1209 Orange Street, New
Castle County Wilmington, Delaware 19801 in the City of Wilmington, County of
New Castle. The name of the registered agent of the corporation at such address
is The Corporation Trust Company.

      THIRD: The purpose of the corporation is to engage in any lawful act or
activity for which corporations may be organized under the General Corporation
Law of the State of Delaware.

      FOURTH: The total number of shares of stock which the corporation shall
have authority to issue is One Thousand (1000) shares of common stock having a
par value of $.001 per share ("Common Stock").

      FIFTH: The incorporator is Thomas C. Kuhn III, whose mailing address is
c/o Bridgetech Holdings International, Inc., 777 S. Highway 101, Suite 215,
Solana Beach, California 92075.

      SIXTH: Election of directors need not be by ballot.

      SEVENTH: In furtherance and not in limitation of the powers conferred by
the laws of the State of Delaware, the board of directors is expressly
authorized to adopt, amend or repeal the bylaws of the corporation.

      EIGHTH: A director of the corporation shall not be personally liable to
the corporation or its stockholders for monetary damages for breach of fiduciary
duty as a director, except for liability (a) for any breach of the director's
duty of loyalty to the corporation or its stockholders, (b) for acts or
omissions not in good faith or which involve intentional misconduct or a knowing
violation of law, (c) under Delaware General Corporation Law Section 174, or (d)
for any transaction from which the director derived an improper personal
benefit. If the Delaware General Corporation Law is amended after the date of
this certificate of incorporation to further eliminate or limit the personal
liability of directors, then the liability of a director of the corporation
shall be eliminated or limited to the fullest extent permitted by the Delaware
General Corporation Law, as so amended. Any repeal or modification of this
Article by the stockholders of the corporation shall not adversely affect any
right or protection of a director of the corporation existing at the time of
such repeal or modification.

                                       24

<PAGE>

      NINTH: The corporation reserves the right to amend and repeal any
provision contained in the certificate of incorporation in the manner prescribed
by the laws of the State of Delaware. All rights herein conferred are granted
subject to this reservation.

      DULY EXECUTED and delivered by the incorporator, under seal, for the
purpose of forming a corporation under the laws of the State of Delaware and
making, filing and recording this certificate of incorporation, and who does
hereby certify that the facts stated in this certificate of incorporation are
true, all on May 25, 2005.

                                                   _____________________________
                                                   Thomas C. Kuhn III
                                                   as incorporator

                                    * * * * *

                                       25

<PAGE>

                                                                       EXHIBIT B

                                 FORM OF BYLAWS

See attached.

                                       26
<PAGE>

================================================================================

                                     BYLAWS

                                       OF

                                  [__________]

                            (a Delaware Corporation)

================================================================================

                                       27
<PAGE>

                                TABLE OF CONTENTS
<TABLE>
<S>                                                                     <C>
ARTICLE 1: DEFINITIONS..............................................    29
   1.1      Definitions.............................................    29
ARTICLE 2: STOCK CERTIFICATES.......................................    30
   2.1      Stock Certificates......................................    30
   2.2      List of Stockholders....................................    30
   2.3      Transfers of Stock......................................    30
   2.4      Lost Certificates.......................................    30
ARTICLE 3: STOCKHOLDERS' MEETINGS...................................    30
   3.1      Annual Meetings of Stockholders.........................    30
   3.2      Special Meetings of Stockholders........................    30
   3.3      Notice..................................................    30
   3.4      Quorum..................................................    31
   3.5      Voting..................................................    31
   3.6      Adjournment.............................................    31
   3.7      Presiding Officer.......................................    31
   3.8      Written Consent of the Stockholders.....................    32
ARTICLE 4: BOARD OF DIRECTORS.......................................    32
   4.1      Powers of Board.........................................    32
   4.2      Number of Board; Conduct of Meetings of Board...........    32
   4.3      Removal of Board........................................    32
   4.4      Board Vacancies.........................................    32
   4.5      Meetings; Notice........................................    33
   4.6      Executive and Other Committees..........................    34
   4.7      Reliance on Records and Third Parties...................    34
ARTICLE 5: OFFICERS.................................................    35
   5.1      Officers; Election......................................    35
   5.2      President...............................................    35
   5.3      Secretary...............................................    35
   5.4      Vice Presidents.........................................    35
   5.5      Appointment of Officers and Agents......................    35
   5.6      Removal of Officers and Agents..........................    35
   5.7      Vacancies...............................................    35
ARTICLE 6: SEAL.....................................................    36
   6.1      Seal....................................................    36
ARTICLE 7: INDEMNIFICATION AND INSURANCE............................    36
   7.1      Indemnification.........................................    36
   7.2      Insurance...............................................    37
ARTICLE 8: MISCELLANEOUS............................................    37
   8.1      Voting of Securities Owned by the Corporation...........    37
   8.2      Registered Offices......................................    37
ARTICLE 9: AMENDMENT................................................    38
   9.1      Amendment...............................................    38
</TABLE>

<PAGE>

                                     BYLAWS

                                       OF

                                  [__________]
                            (A Delaware Corporation)

                             ARTICLE I. DEFINITIONS

      1.1 Definitions.

            The following terms used in the Bylaws have the meanings set forth
      below:

            (a)   "Certificate of Incorporation" means the certificate of
                  incorporation of the Corporation as amended from time to time.

            (b)   "Board" means the Board of Directors of the Corporation.

            (c)   "Bylaws" means these bylaws as amended or restated from time
                  to time.

            (d)   "Corporation" means the Delaware corporation named _________.

            (e)   "DGCL" refers to the General Corporation Law of the State of
                  Delaware or any successor law of the State of Delaware, and a
                  reference to a particular section of the DGCL is a reference
                  to successor sections of such law or successor law.

            (f)   "Section" means a section of the Bylaws.

            (g)   "Stockholders" means the stockholders of the Corporation.

For purposes of the Bylaws: (i) titles and captions of or in, and the table of
contents of, the Bylaws are inserted only as a matter of convenience and for
reference and in no way define, limit, extend or describe the scope of the
Bylaws or the intent of any of their provisions; and (ii) "including" and other
words or phrases of inclusion, if any, shall not be construed as terms of
limitation, so that references to "included" matters shall be regarded as
non-exclusive, non-characterizing illustrations.

<PAGE>

                         ARTICLE II. STOCK CERTIFICATES

      2.1 Stock Certificates. Stock certificates shall be issued in consecutive
order and shall be numbered in the order in which they are issued. They shall be
signed by the President or the Secretary (any of which signatures may be a
facsimile), and the seal of the Corporation or a facsimile of it shall be
affixed to the stock certificate.

      2.2 List of Stockholders. The Corporation shall maintain an alphabetical
record of the names and addresses of its Stockholders and the number of shares
of stock held by each, which shall be maintained and made available in
accordance with the DGCL.

      2.3 Transfers of Stock. Transfers of stock of the Corporation shall be
made in the stock records of the Corporation upon surrender of the certificate
for such stock signed by the person in whose name the certificate is registered
or on his behalf by a person legally authorized to so sign (or accompanied by a
separate stock transfer power so signed) and otherwise in accordance with and
subject to any other restrictions placed on the transfer of such stock.

      2.4 Lost Certificates. The Corporation may issue a new stock certificate
in place of any certificate or certificates previously issued by the Corporation
and alleged to have been lost or destroyed upon the making of an affidavit of
that fact by the person claiming the certificate to be lost or destroyed and, if
the President in his sole discretion deems it appropriate, the delivery of a
commercial indemnity bond issued by a company approved by him in such sum as he
may direct as indemnity against any claim that may be made against the
Corporation with respect to the certificate alleged to have been lost or
destroyed.

                       ARTICLE III. STOCKHOLDERS' MEETINGS

      3.1 Annual Meetings of Stockholders. The annual meeting of the
Stockholders of the Corporation shall be held within the first four months after
the end of each fiscal year of the Corporation at such time and place, within or
without the State of Delaware, as may from time to time be fixed by the Board or
the President; provided that the failure to hold an annual meeting shall not
work a forfeiture of or otherwise affect valid corporate acts.

      3.2 Special Meetings of Stockholders. Special meetings of the Stockholders
may be called at any time by the Board or the President, or by the Corporation
upon the written request of the holder or holders of at least 15 percent of the
outstanding shares of stock of the Corporation. Special meetings of the
Stockholders shall be held at such time and place, within or without the State
of Delaware, as may be determined by the person or persons calling the meeting.

      3.3 Notice. The Secretary or the officer or persons calling the meeting
shall deliver a written notice of the place, if any, day and time of each
meeting of the Stockholders, not less than ten (10) nor more than sixty (60)
days before the date of the meeting, to each Stockholder of record entitled to
vote at such meeting. Such notice shall be given in any manner permitted by

<PAGE>

the DGCL. If mailed, such notice shall be deemed to be delivered five (5) days
after it is deposited in the United States mail with first class postage thereon
prepaid, addressed to the Stockholder at his address as it appears on the stock
records of the Corporation. The notice of a special meeting of the Stockholders
shall state the purpose or purposes for which the meeting is called. If the
meeting is to be held by means of remote communication pursuant to the DGCL, the
notice shall state the means of remote communications, if any, by which
Stockholders and proxy holders may be deemed to be present in person and vote at
such meeting. Notice of a meeting of the Stockholders need not be given to any
Stockholder who signs a waiver of notice, either before or after the meeting.
Attendance of a Stockholder at a meeting, either in person or by proxy, shall of
itself constitute waiver of notice of such meeting and waiver of any and all
objections to the place of the meeting, the time of the meeting, and the manner
in which it has been called or convened, except when a Stockholder attends the
meeting solely for the purpose of stating, at the beginning of the meeting, any
such objection or objections to the transaction of business.

      3.4 Quorum. At all meetings of the Stockholders, the holders of a majority
of the outstanding shares of stock of the Corporation entitled to vote,
represented in person or by proxy, shall constitute a quorum for the transaction
of business.

      3.5 Voting. Except as otherwise required by law, the Bylaws or any lawful
agreement between or among the Stockholders, all resolutions adopted and
business transacted shall require the favorable vote of the holders of a
majority of the shares of stock represented at the meeting and entitled to vote
on the subject matter. Except as otherwise required by law, by the Certificate
of Incorporation, by filings with the Delaware Secretary of State fixing and
determining the voting rights of the stock of the Corporation or by the Bylaws,
at any meeting of the Stockholders, each Stockholder of the Corporation shall
have one vote, in person or by proxy, for each share of stock having voting
rights standing in his name on the books of the Corporation at the record date
fixed or otherwise determined for such meeting.

      3.6 Adjournment. The holders of a majority of the shares of stock
represented at a meeting, whether or not a quorum is present, may adjourn such
meeting from time to time. If a quorum is not present, the holders of the shares
of stock present in person or represented by proxy at the meeting, and entitled
to vote, shall have the power, by the affirmative vote of the holder of such
shares of stock, which represent a majority of the votes which may be cast by
the holders of such shares of stock, to adjourn the meeting to another time
and/or place. Unless the adjournment is for more than thirty (30) days or unless
a new record date is set for the adjourned meeting, no notice of the adjourned
meeting need be given to any Stockholder provided that the time, place, if any,
and the means of remote communication, if any, by which Stockholders and proxy
holders may be deemed to be present in person and vote at the adjourned meeting
were announced at the meeting at which the adjournment was taken. At the
adjourned meeting, the Corporation may transact any business which might have
been transacted at the original meeting.

      3.7 Presiding Officer. The President shall preside at meetings of the
Stockholders; provided, however, that the President may delegate his authority
to preside at meetings of the Stockholders pursuant to Section 5.2.

<PAGE>

      3.8 Written Consent of the Stockholders. Any action required to be taken
at a meeting of the Stockholders of the Corporation, or any action that may be
taken at a meeting of the Stockholders, may be taken without a meeting if a
consent in writing setting forth the action so taken shall be signed by persons
who would be entitled to vote at a meeting those shares of stock having voting
power to cast not less than the minimum number of votes that would be necessary
to authorize or take such action at a meeting at which all shares of stock
entitled to vote were present and voted. Prompt notice shall be given of the
taking of corporate action without a meeting by less than unanimous written
consent to those Stockholders on the record date whose shares of stock were not
represented on the written consent. For purposes of written consent by the
Stockholders, the record date for determining Stockholders entitled to take
action pursuant to this Section 3.8 shall be the date when the consent is first
executed and action shall be deemed taken when executed by the last necessary
signature.

                         ARTICLE IV. BOARD OF DIRECTORS

      4.1 Powers of Board. Subject to the Certificate of Incorporation, the
Bylaws, and any lawful agreement between or among the Stockholders, including
that certain Joint Venture Agreement, dated as of April 10, 2005, by and between
Bridgetech Holdings International, Inc. and Amcare Labs International, Inc. (the
"Joint Venture Agreement") and any management agreement contemplated thereby,
the business and affairs of the Corporation shall be managed by the Board.

      4.2 Number of Board; Conduct of Meetings of Board. The members of the
Board of Directors shall be determined as provided in the Joint Venture
Agreement. In the event that the Joint Venture Agreement shall no longer be in
effect, the Board shall consist of three directors, each of whom shall be
elected at an annual meeting of the Stockholders, to serve until his successor
is elected and qualified, or until his earlier death, resignation or removal.

      4.3 Removal of Board. Members of the Board of Directors shall be removed
only as provided in the Joint Venture Agreement. In the event that the Joint
Venture Agreement shall no longer be in effect, at any meeting of the
Stockholders with respect to which notice of such purpose has been given, the
entire Board or any individual director may be removed, with or without cause,
by the affirmative vote of the holders of a majority of the shares of stock of
the Corporation entitled to vote.

      4.4 Board Vacancies. Except as otherwise provided in this Section 4.4 or
in the Joint Venture Agreement, any vacancy occurring in the Board may be filled
by the affirmative vote of a majority of the remaining directors though less
than a quorum of the Board, or by the sole remaining director, as the case may
be, or, if the vacancy is not so filled, or if no director remains, by the
Stockholders. Any vacancy arising as a result of the removal of a director by
the Stockholders may be filled by the Stockholders or, if the Stockholders so
authorize, by the remaining director or directors, but only for the unexpired
term of his predecessor in office. The Board may fill a vacancy created by an
increase in the number of directors resulting from an amendment of Section 4.2,
but only for a term of office continuing until the next annual election of
directors by the Stockholders and the election and qualification of a successor.

<PAGE>

      4.5 Meetings; Notice.

            (a) Time and Location. The Board shall meet annually immediately
following the annual meeting of the Stockholders; provided that the failure to
hold the annual meeting shall not work a forfeiture or otherwise affect valid
corporate acts. A special meeting of the Board may be called at any time by the
President, or by any two directors, on ten (10) days' notice.

            (b) Notice. Notice shall be given (i) in person, either orally or in
writing (which includes a telephone call to the director, but does not include
either (A) a telephone call to such directors' assistant or (B) the leaving of a
message), (ii) by nationally recognized next business day delivery service for
next business day delivery, (iii) by fax, or (iv) by electronic mail. Such
notice shall be addressed to the director at his address as it appears on the
stock records of the Corporation or, if he is not a Stockholder, at his business
address. Notice of a special meeting may be waived by an instrument in writing.
Attendance of a director at a meeting shall constitute a waiver of notice of the
meeting and waiver of any and all objections to the place of the meeting, the
time of the meeting and the manner in which it has been called or convened,
except when a director states, at the beginning of the meeting, any such
objection or objections to the transaction of business. Any meeting of the Board
may be held within or without the State of Delaware at such place as may be
determined by the person or persons calling the meeting.

            (c) Quorum. Unless otherwise provided in the Joint Venture
Agreement, all of the directors shall constitute a quorum for the transaction of
business.

            (d) Voting. Except as otherwise provided in the Certificate of
Incorporation, these Bylaws or the Joint Venture Agreement, all resolutions
adopted and all business transacted by the Board shall require the affirmative
vote of a majority of the directors present at a meeting at which a quorum is
present.

            (e) Presiding Officer. The Board shall select a director as chairman
for each meeting.

            (f) Written Consent of Board. Any action required to be taken at a
meeting of the Board, or any action that may be taken at a meeting of the Board,
may be taken without a meeting if a consent in writing setting forth the action
taken shall be signed by all the directors and shall be filed with the minutes
of the proceedings of the directors.

            (g) Telephonic Meetings of Board. Any action required to be taken at
a meeting of the Board, or any action that may be taken at a meeting of the
Board, may be taken at a meeting held by means of conference telephone or
similar communications equipment by means of which all persons participating in
the meeting can hear each other. Participation in such a meeting shall
constitute presence in person at such meeting. In all other respects the
provisions of Article 4 of the Bylaws with respect to meetings of the Board
shall apply to such a meeting.

<PAGE>

      4.6 Executive and Other Committees. The Board may designate, by resolution
adopted by a majority of the Board, from among its members an executive
committee and one or more other committees, each consisting of one or more
directors, subject to the following:

            (a) Each such committee shall have and may exercise, consistent with
and to the extent provided in the resolution of the Board designating such
committee, all the authority of the Board, but no such committee shall have the
power or authority in reference to (i) approving or adopting, or recommending to
the Stockholders, any action or matter expressly required by the DGCL to be
submitted to Stockholders for approval, or (ii) adopting, amending or repealing
any bylaw of the Corporation.

            (b) Each member of any such committee shall hold office until the
next regular annual meeting of the Board following his designation and until his
successor is designated, elected and qualified. Any vacancy in any such
committee may be filled by a resolution adopted by a majority of the Board. The
Board, by resolution adopted by a majority of the Board, may designate one or
more directors as alternate members of any such committee, who may act in the
place and stead of any absent member or members at any meeting of such
committee. Any member of any such committee may be removed at any time with or
without cause by resolution adopted by a majority of the Board. Any member of
any such committee may resign from such committee at any time by giving written
notice to the President or Secretary of the Corporation, and unless otherwise
specified therein, the acceptance of such resignation shall not be necessary to
make it effective.

            (c) Unless the Board otherwise provides, each committee designated
by the Board may make, alter and repeal rules for the holding of its meetings
and the conduct of its business, subject to the following: (i) a majority of the
entire authorized number of members of such committee shall constitute a quorum
for the transaction of business; (ii) the vote of a majority of the members
present at a meeting at the time of such vote if a quorum is then present shall
be the act of such committee; and (iii) in other respects each committee shall
hold its meetings and conduct its business in the same manner as does the Board
pursuant to Article 4 of the Bylaws (including, without limitation, the taking
of action without a meeting if a consent in writing, setting forth the action so
taken, shall be signed by all of the members of such committee and be filed with
the minutes of the proceedings of such committee). Each such committee shall
keep minutes or other records of its proceedings and shall report its actions to
the Board as requested and at regularly scheduled meetings of the Board.

            (d) The designation of any such committee and the delegation thereto
of authority shall not operate to relieve the Board, or any member of the Board,
of any responsibility imposed by law.

      4.7 Reliance on Records and Third Parties. A member of the Board or a
member of any committee designated by the Board shall, in the performance of
such member's duties, be fully protected in relying in good faith upon the
records of the Corporation and upon such information, opinions, reports or
statements presented to the Corporation by any of the Corporation's officers or
employees, or committees of the Board, or by any other person as to

<PAGE>

matters the member reasonably believes are within such other person's
professional or expert competence and who has been selected with reasonable care
by or on behalf of the Corporation.

                               ARTICLE V. OFFICERS

      5.1 Officers; Election. The Board shall elect a President and a Secretary,
and may elect one or more Vice Presidents, and such other officers, assistant
officers or agents as the Board shall determine. Any two or more offices may be
held by the same person. A failure to elect officers shall not dissolve or
otherwise affect the Corporation.

      5.2 President. Subject to the direction of the Board, the President shall
be the chief operating officer of the Corporation and have general supervision
of the day-to-day affairs of the Corporation. When present, he or she shall
report to the Stockholders and directors at all regular meetings. The President
shall have the power to enter into contracts on behalf of the Corporation; shall
sign or countersign all certificates, contracts or other instruments on behalf
of the Corporation as authorized by the Board; and shall have all such other
duties and powers as are incident to his office or properly prescribed by the
Board. The President shall exercise all of the functions and perform all of the
duties of the chief executive officer of the Corporation. If he has not
delegated such authority, the President shall preside at meetings of the
Stockholders and, if he is a director, at meetings of the Board.

      5.3 Secretary. The Secretary shall keep minutes of all meetings of the
Stockholders and Board, shall have charge of the minute books, stock records and
seal of the corporation, shall have the authority to certify as to the corporate
books and records, and shall perform such other duties and have such other
powers as may from time to time be delegated to him by the President or the
Board.

      5.4 Vice Presidents. The Vice Presidents, if any, shall perform such
duties and exercise such powers as the President or the Board shall request or
delegate and, unless the Board, or the President otherwise provides, shall
perform such other duties as are generally performed by Vice Presidents with
equivalent restrictions, if any, on title.

      5.5 Appointment of Officers and Agents. The Board or the President may
appoint one or more Vice Presidents and such other officers, assistant officers
and agents as the Board or the President may determine. Any such officers,
assistant officers or agents so appointed shall perform such duties as are set
forth in the Bylaws and as the action appointing him provides, and, unless such
action otherwise provides, such appointed officers, assistant officers and
agents shall perform such duties as are generally performed by elected officers,
assistant officers or agents having The same title.

      5.6 Removal of Officers and Agents. Any officer, assistant officer or
agent elected or appointed by the Board may be removed by the Board. Any
officer, assistant officer or agent appointed by the President may be removed by
the President or by the Board whenever in his or its judgment the best interests
of the Corporation will be served thereby.

      5.7 Vacancies. Any vacancy, however occurring, in any office may be filled
by the Board.

<PAGE>

                                ARTICLE VI. SEAL

         6.1 Seal. The seal of the Corporation shall be in such form as the
Board may from time to time determine. In the event it is inconvenient to use
such a seal at any time, the words "Corporate Seal" or the word "Seal"
accompanying the signature of an officer signing for and on behalf of the
Corporation shall be the seal of the Corporation. The seal shall be in the
custody of the Secretary and affixed by him on the stock certificates and such
other papers as may be directed by law, by the Bylaws or by the Board.

                   ARTICLE VII. INDEMNIFICATION AND INSURANCE

      7.1 Indemnification.

      (a) General. The Corporation shall indemnify each person who is or was a
director or officer of the Corporation (including the heirs, executors,
administrators or estate of such person) or is or was serving at the request of
the Corporation as a director or officer of another corporation, partnership,
joint venture, trust or other enterprise to the full extent permitted under DGCL
Section 145(a), (b) and (c) or any other provisions of the laws of the State of
Delaware.

      (b) Procedure. If any such indemnification is requested pursuant to the
foregoing, the Board shall cause a determination to be made (unless a court has
ordered the indemnification or indemnification is required by DGCL Section
145(c)) pursuant to DGCL Section 145(d) as to whether indemnification of the
party requesting indemnification is proper in the circumstances because he has
met the applicable standard of conduct set forth in DGCL Sections 145(a) or (b).
Upon any such determination that such indemnification is proper, the Corporation
shall make indemnification payments of liability, cost, payment or expense
asserted against, or paid or incurred by, him in his capacity as such a director
or officer to the maximum extent permitted by said sections of such laws.

      (c) Interim Payment of Expenses. Expenses incurred by a person who is or
was a director or officer of the Corporation (including the heirs, executors,
administrators or estate of such person) or is or was serving at the request of
the Corporation as a director or officer of another corporation, partnership,
joint venture, trust or other enterprise in defending a civil or criminal
action, suit, or proceeding may be paid by the Corporation in advance of the
final disposition of such action, suit or proceeding, as authorized by the
Board, upon receipt of an agreement or an undertaking by or on behalf of such
person to repay such amount, unless it is ultimately determined that he or she
is not entitled to be indemnified by the Corporation as authorized in, or as
permitted by, this Article 7. The Board may pay such expenses of such person
upon such other terms and conditions as the Board deems appropriate.

      (d) Subsequent Amendment. No amendment, termination or other elimination
of this Article 7 or of any relevant provisions of the DGCL or any other
applicable laws shall affect or diminish in any way the rights to
indemnification under this Article 7 with respect to any action,

<PAGE>

suit or proceeding arising out of, or relating to, any event or act or omission
occurring or fact or circumstance existing prior to such amendment, termination
or other elimination.

      (e) Other Rights. The indemnification and advancement of expenses provided
by, or granted pursuant to, the other subsections of this Section 7.1 shall not
be deemed exclusive of any other rights to which a director or officer, seeking
indemnification or advancement of expenses may be entitled under any applicable
law, agreement, vote of Stockholders or disinterested directors or otherwise,
both as to action in his official capacity and as to action in any other
capacity while holding such office; provided, however, that indemnification of a
director shall not be permitted with respect to liability (i) for any breach of
the director's duty of loyalty to the Corporation or its Stockholders, (ii) for
acts or omissions not in good faith or which involve intentional misconduct or a
knowing violation of law, (iii) under DGCL Section 174, or (iv) for any
transaction from which the director derived an improper personal benefit.
Nothing contained in this Article 7 shall be deemed to prohibit, and the
Corporation is specifically authorized to enter into, agreements which provide
indemnification rights and procedures permitted by the DGCL.

      (f) Continuation of Right to Indemnification. All rights to
indemnification under this Article 7 (including those arising pursuant to
subsection (e) above) shall continue as to a person who has ceased to be a
director or officer, shall inure to the benefit of heirs, executors,
administrators and the estate of such person, and shall be deemed to be a
contract between the Corporation and each such person or entity. This Article 7
shall be binding upon any successor corporation to the Corporation, whether by
way of merger, consolidation or otherwise.

      (g) Savings Clause. If this Article 7 or any portion hereof shall be
invalidated on any ground by any court of competent jurisdiction, then the
Corporation shall nevertheless indemnify persons or entities specified in this
Article 7 to the full extent permitted by any applicable portion of this Article
7 that shall not have been invalidated and to the full extent permitted by
applicable law.

      7.2 Insurance. The Corporation may purchase and maintain insurance at its
expense, to protect itself and any such person or entity against any such
liability, cost, payment or expense whether or not the Corporation would have
the power to indemnify such person or entity against such liability, cost,
payment or expense.

                           ARTICLE VIII. MISCELLANEOUS

      8.1 Voting of Securities Owned by the Corporation. The President, any
Vice-President or the Secretary of the Corporation or such other person
designated by the Board shall have authority to vote shares of stock or any
other securities owned by the Corporation and to execute proxies and written
waivers and consents in relation thereto.

      8.2 Registered Offices. The initial registered office of the Corporation
in the State of Delaware and the name of the Corporation's registered agent
shall be as designated in the Certificate of Incorporation and may be changed as
the officers of the Corporation shall from time to time determine.

<PAGE>

                              ARTICLE IX. AMENDMENT

      9.1 Amendment. The Bylaws may be amended by the Stockholders or by the
Board either by written consent or approved at a meeting, in each case in
accordance with the provisions of the Bylaws and applicable law. The
Stockholders may prescribe that any or all provisions of the Bylaws adopted by
them shall not be altered, amended or repealed by the Board.

                                    * * * * *

<PAGE>

                                                                       EXHIBIT C

                         FORM OF STOCKHOLDERS AGREEMENT

See attached.

<PAGE>

                              STOCKHOLDER AGREEMENT

      THIS STOCKHOLDER AGREEMENT (this "Agreement") is made as of this ___ day
of _______, 2005, by and among _____________, a Delaware corporation (the
"Company"), and those certain individuals listed as Common Stockholders on
Schedule 1 attached hereto (collectively, the "Common Stockholders"). The Common
Stockholders and their successors and assigns, and each future stockholder of
the Company who signs a signature page to this Agreement are hereinafter
sometimes referred to collectively as the "Stockholders".

                                   Background

      A. In connection with the transactions described in that certain Joint
Venture Agreement by and among Bridgetech Holdings International, Inc.
("Bridgetech") and Amcare Labs International, Inc. ("Amcare"), dated as of April
10, 2005 (the "Joint Venture Agreement"), the Company has agreed to issue up to
1,000 shares of the Company's $.001 par value of common stock (the "Common
Stock") to Bridgetech and Amcare. Any term used herein but not defined herein
shall have the meaning given that term in the Joint Venture Agreement.

      B. The Company and the Stockholders desire to enter into this Agreement
for the purpose, among others, of prescribing the manner and terms by which the
Stockholders' shares of Common Stock (the "Shares"), may be transferred.

      C. The execution and delivery of this Agreement is a condition to the
Closing under the Joint Venture Agreement.

      In consideration of the premises and the covenants and undertakings
hereinafter set forth, the parties hereto agree as follows:

      1. CAPITALIZATION. Set forth on Schedule 1 attached hereto is a list of
all the Stockholders of the Company and their respective ownership of Shares
immediately following the Closing.

      2. TRANSFER RESTRICTIONS ON SHARES.

      (a) General. No holder of Shares shall sell, offer, assign, pledge or
otherwise dispose of any interest in any Shares (whether with or without
consideration and whether voluntarily or involuntarily or by operation of law),
except pursuant to (i) any sale of Shares to the public pursuant to an
underwritten offering registered under the Securities Act of 1933, as amended
(the "Securities Act"), or to the public through a broker, dealer or market
maker pursuant to the provisions of Rule 144 adopted under the Securities Act or
(ii) the provisions of this Section 2 or Section 3.

      (b) Permitted Transfers. A Stockholder may transfer all or a portion of
its Shares (i) in the case of a Stockholder that is an individual, to a spouse,
sibling, lineal ancestor or descendant, natural or adopted, or to a trust or
other estate planning entity for the benefit of the

<PAGE>

Stockholder or any of such persons; and (ii) in the case of a Stockholder that
is a Person other than an individual, to or among its Affiliates (clauses (i)
and (ii) collectively referred to herein as "Permitted Transferees"). As a
condition to any transfer pursuant to this Section 2(b), the transferee must
agree in writing that it and its heirs, successors and assigns, shall be subject
to and bound by the provisions of this Agreement. Notwithstanding the foregoing,
no party hereto shall avoid the provisions of this Agreement by making one or
more transfers to Permitted Transferees and then disposing of all or any portion
of such party's interest in any such Permitted Transferee. For purposes of this
Agreement, an "Affiliate" of a Person means any Stockholder, partner, member or
other equity owner of such Person or any other Person directly or indirectly
controlling, controlled by or under common control with such Person. "Person"
means an individual, a partnership, a corporation, a limited liability company,
an association, a joint stock company, a trust, a joint venture, an
unincorporated organization and a governmental entity or any department, agency
or political subdivision thereof.

      (c) Right of First Refusal.

            (i) Notice of Offer to Sell Shares. Except as provided in Sections
      2(a) and 2(b) above, if any Stockholder shall desire to sell, exchange or
      in any other manner dispose of all or any of the Shares now owned or
      hereafter acquired by it (such Stockholder being hereinafter referred to
      as the "Selling Stockholder"), it must first receive a bona fide written
      offer from a third-party prospective purchaser to purchase such Shares,
      and then deliver to other Stockholders (the "Non-Selling Stockholders") a
      written notice ("Notice") containing the following information:

            (A)   The name and address of the prospective purchaser of such
                  Shares;

            (B)   The number of Shares that the Selling Stockholder desires to
                  sell;

            (C)   The price being offered to the Selling Stockholder and, in
                  reasonable detail, the terms of payment and any other terms
                  and conditions of such offer, including but not limited to the
                  fair market value (as hereinafter defined) of any non-cash
                  consideration; and

            (D)   The proposed closing date for the transaction, which shall be
                  not less than sixty-five (65) days or more than one hundred
                  twenty (120) days after the date of delivery of the Notice.

            (ii) Offer to Non-Selling Stockholders. For a period of sixty (60)
      days after the giving of the Notice by the Selling Stockholder, the
      Non-Selling Stockholders shall have the option to purchase all or any of
      their pro-rata portion of the Shares that are proposed to be sold at the
      price and upon the terms and conditions set forth in the Notice. Such
      option shall be exercisable by written notice from such Non-Selling
      Stockholder to the Selling Stockholder within such sixty (60) day period.
      A failure by any Non-Selling Stockholder to give written notice of
      exercise within such sixty (60) day period shall be deemed a rejection by
      such Non-Selling Stockholder of its option to purchase. If a Non-
<PAGE>

      Selling Stockholder does not exercise its option to purchase all the
      Shares to which it is first entitled, each remaining Non-Selling
      Stockholder shall then have the option to purchase its pro rata portion of
      the Shares that will not be purchased by the other Non-Selling
      Stockholders, which option shall be exercisable by notice in writing to
      the Selling Stockholder and to each of the other Non-Selling Stockholders
      within five (5) days after the date of express rejection by all other
      Non-Selling Stockholders or the expiration of the options to the
      Non-Selling Stockholder who did not elect to purchase such Shares,
      whichever is earlier. For purposes of the foregoing sentence, the Shares
      available for purchase shall be allocated pro rata among the Non-Selling
      Stockholders desiring to purchase such Shares, which allocation shall be
      based on the number of Shares owned by each Non-Selling Stockholder in
      relation to the total number of Shares held by all Non-Selling
      Stockholders who wish to purchase Shares.

            (iii) Non-Cash Consideration for Shares. If any consideration to be
      received by a Selling Stockholder from a prospective purchaser of its
      Shares consists of property other than cash, then the Non-Selling
      Stockholders who exercise their option(s) to purchase the Selling
      Stockholder's Shares, may deliver to the Selling Stockholder, in payment
      of the non-cash portion of the purchase price for the Shares proposed to
      be sold, an amount of cash equal to the fair market value of the non-cash
      consideration that has been offered to the Selling Stockholder. For
      purposes hereof, the "fair market value" of non-cash consideration shall
      in each case be agreed upon by the Selling Stockholder and the Non-Selling
      Stockholder purchasing its Shares as provided in this Agreement, or, in
      the absence of such agreement, such "fair market value" shall be
      determined by an appraisal thereof by three independent qualified
      appraisers, one being selected by the Selling Stockholder, one being
      selected by the Non-Selling Stockholder hereto desiring to purchase the
      Selling Stockholder's Shares, and the third appraiser being selected by
      the two appraisers thus chosen. The cost of any such appraisal shall be
      borne equally by the parties to the appraisal proceeding. All decisions to
      be made by the Non-Selling Stockholders purchasing Shares from the Selling
      Stockholder shall be made by the affirmative vote of those holding a
      majority of Shares held by all such Non-Selling Stockholders. Any closing
      provided for herein may be extended for such reasonable period of time as
      may be necessary in order for a required appraisal to be completed. In the
      event of an appraisal pursuant to this Section 2, the parties agree to be
      bound thereby.

            (iv) Closings. If any Non-Selling Stockholder shall exercise an
      option to purchase that is granted to such Non-Selling Stockholder in this
      Section 2, the closing of the purchase and sale transaction shall be held
      at the principal office of the Company on a date designated by the
      purchaser or purchasers, which date in no event shall be later than 90
      days after the Selling Stockholder gives the Notice. If there is more than
      one Non-Selling Stockholder purchasing the Shares, the Selling Stockholder
      may require that all such Non-Selling Stockholders close concurrently on
      the same date.

            (v) Right to Transfer. If the Non-Selling Stockholders do not elect
      to purchase all the Shares that a Selling Stockholder desires to sell,
      subject to Section 2(d) below, the Selling Stockholder shall have the
      right to sell the Shares to the prospective purchaser named in the Notice
      on the terms and conditions set forth in the Notice until such date that
      is 120 days after the date of the Notice. In addition, as a condition to
      any

<PAGE>

      such sale, the purchaser of the Shares must agree in writing that it and
      its heirs, successors and assigns, shall be subject to and bound by the
      provisions of this Agreement. In the event that the Selling Stockholder
      does not sell or otherwise dispose of such Shares within the such period
      of time, the right of first offer provided for in this Section 2(c) shall
      continue to be applicable to any subsequent disposition of such Shares.

      (d) Right of Co-Sale (Tag-Along). In the event that a Selling Stockholder
proposes to dispose of Shares representing not less than fifteen percent(15%) of
the then-outstanding Shares to a third party (other than in accordance with
Sections 2(a) and 2(b)), after compliance with the provisions of Section 2(c),
the other Stockholders shall have the right to offer and sell a proportionate
number of Shares to the prospective purchaser acquiring such Selling
Stockholder's Shares, at the same price and on the same terms and conditions as
outlined in the Notice (the "Co-Sale Right"), in accordance with the following
procedure:

            (i) Such Selling Stockholder shall, prior to sale and after
      compliance with the provisions of Section 2(c), give notice (the "Co-Sale
      Notice") to the Stockholders of the Co-Sale Right and the aggregate number
      of Shares proposed to be sold to the third-party purchaser (taking into
      account any Offered Shares to be purchased by Non-Selling Stockholders
      pursuant to Section 2(c) above).

            (ii) Each Stockholder shall have fifteen (15) days after receipt of
      such notice to determine if it desires to offer Shares to the third-party
      acquiring such Selling Stockholder's Shares. A failure by a Stockholder to
      give written notice of exercise within such fifteen (15) day period shall
      be deemed a rejection by such Stockholder of its Co-Sale Right.

            (iii) Such Selling Stockholder shall cause the proposed purchaser to
      offer, in writing to each Stockholder, if Stockholder has elected to
      participate in the sale of the Shares (a "Participating Stockholder"), to
      purchase at the offer price indicated in the Co-Sale Notice, all or any
      part of that number of Shares equal to the product obtained by multiplying
      (i) the aggregate number of offered Shares (less any Offered Shares to be
      purchased by Non-Selling Stockholders pursuant to Section 2(c) above) by
      (ii) a fraction, the numerator of which is the number of Shares owned by
      such Participating Stockholder immediately before the time of the sale and
      the denominator of which is the sum of (x) the number of the Shares then
      owned by all Participating Stockholders and (y) the number of Shares owned
      by the Selling Stockholder. The Shares to be transferred by the Selling
      Stockholder shall be correspondingly reduced by the aggregate sum of such
      product for such Participating Stockholder.

            (iv) A Participating Stockholder shall effect its participation in
      the sale by promptly delivering to the Selling Stockholder for transfer to
      the proposed purchaser one or more certificates, properly endorsed for
      transfer, which represent the type and number of Shares that such
      participant elects to sell.

            (v) The stock certificate or certificates that the Participating
      Stockholder delivers to the Selling Stockholder pursuant to subsection
      (iv) above shall be transferred

<PAGE>

      to the proposed purchaser in consummation of the sale of the offered
      Shares (together with the Selling Stockholders Shares) pursuant to the
      terms and conditions specified in the Co-Sale Notice, and the Selling
      Stockholder shall concurrently therewith remit to the Participating
      Stockholder that portion of the sale proceeds to which the Participating
      Stockholder is entitled by reason of its participation in such sale.

<PAGE>

            (e) Prohibited Transfers Void. Any purported transfer of Shares in
violation of this Agreement shall be void and shall not transfer any interest or
title to any Shares to the purported transferee. The Company shall not be
required to transfer on its books any Shares sold or transferred in violation of
any of the provisions set forth in this Agreement or to treat as owner of those
Shares or to pay dividends to any transferee to whom any of those Shares shall
have been so sold or transferred.

      3. SALE OF THE COMPANY (Drag-along Rights).

      (a) If at any time the Board, in accordance with the Bylaws and the Joint
Venture Agreement, approves a sale of all or substantially all the Company's
assets (determined on a consolidated basis) or a sale or exchange of all or
substantially all the Company's outstanding capital stock (whether by merger,
sale, recapitalization, consolidation, reorganization, combination or otherwise)
to any third party in an arm's-length transaction (an "Approved Sale"), each
Stockholder shall vote for, consent to and raise no objections against such
Approved Sale and shall waive any dissenters' rights, appraisal rights or
similar rights in connection therewith. If the Approved Sale is structured as a
sale of stock, each Stockholder shall agree to sell all its Shares and rights to
acquire Shares on the terms and conditions approved by the Board. Each
Stockholder shall take all necessary and desirable actions in its capacity as a
Stockholder in connection with the consummation of the Approved Sale as
requested by the Company (including attendance at meetings in person or by proxy
for purposes of obtaining a quorum and execution of written consents in lieu of
meetings).

      (b) In order to secure each Stockholder's obligation to vote its Shares
and other voting securities of the Company in accordance with the provisions of
this Section 3, each Stockholder hereby appoints the Secretary of the Company
(the "Representative") as true and lawful proxy and attorney-in-fact, with full
power of substitution, to vote all of his, her or its Shares and other voting
securities of the Company for the approval and consummation of an Approved Sale
and all such other matters as expressly provided for in this paragraph. The
Representative may exercise the irrevocable proxy granted to it hereunder at any
time any Stockholder fails to comply with the provisions of this paragraph. The
proxies and powers granted by each Stockholder pursuant to this paragraph (c)
are coupled with an interest and are given to secure the performance of each
Stockholder's obligations and duties under this Section 3. Such proxies and
powers shall be irrevocable for so long as such Stockholder holds any Shares and
shall survive the death, incompetency, disability, bankruptcy or dissolution of
such Stockholder and the subsequent holders of his, her or its Shares.

      (c) The provisions of this Section 3 shall terminate upon the consummation
of an initial public offering by the Company of its debt or equity securities.

      4. REPRESENTATIONS AND WARRANTIES. Each Stockholder represents and
warrants that (a) this Agreement has been duly authorized, executed and
delivered by such Stockholder and constitutes the valid and binding obligation
of such Stockholder, enforceable in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, arrangement, moratorium, fraudulent conveyance or other similar
laws or by general equitable principles, and (b) such Stockholder has not
granted and is not a

<PAGE>

party to any proxy, voting trust or other agreement which is inconsistent with,
conflicts with or violates any provision of this Agreement. No holder of Shares
shall grant any proxy or become party to any voting trust or other agreement
that is inconsistent with, conflicts with or violates any provision of this
Agreement.

      5. LEGEND ON SHARE CERTIFICATES. Upon the execution of this Agreement, the
certificates of Common Stock subject to this Agreement shall bear the following
legend:

      "THE VOTING AND TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE
      ARE SUBJECT TO THE PROVISIONS OF THE STOCKHOLDER AGREEMENT DATED AS OF MAY
      ___, 2005, AS AMENDED AND IN EFFECT FROM TIME TO TIME, AMONG THE COMPANY
      AND THE STOCKHOLDERS NAMED THEREIN, A COPY OF WHICH IS ON FILE AT THE
      OFFICES OF THE COMPANY."

<PAGE>

      6. TRANSFERS; FUTURE SALES; STOCK DIVIDENDS. Prior to (i) the Company
issuing shares to any Person, or (ii) any holder of Shares transferring any
Shares (other than pursuant to an Initial Public Offering) to any Person, the
Company or such holder shall cause the prospective Stockholder or transferee to
be bound by this Agreement and to execute and deliver to the Company and the
other Stockholders a counterpart signature page to this Agreement in the form of
Exhibit A hereto. Such Stockholder or transferee of Shares of Common Stock shall
be deemed to be a Stockholder hereunder in respect of those shares from and
after the date such transferee executes this Agreement. Promptly following such
action, the Company shall amend Schedule 1 attached hereto and provide such
Schedule 1, as amended, to the other parties to this Agreement. If, from time to
time, during the term of this Agreement there is any stock dividend, stock split
or similar other change in the character or amount of any of the outstanding
Common Stock of the Company, then in such event any and all such new,
substituted or additional securities to which the Stockholders are entitled by
reason of their ownership of Common Stock shall be immediately subject to the
terms of this Agreement with the same force and effect as the shares of capital
stock presently subject to this Agreement.

      7. TERMINATION OF AGREEMENT. This Agreement shall terminate upon the
earlier of (a) the consummation of a Qualified Public Offering (as defined
below) of any of its Shares, (b) the liquidation or sale of the Company (whether
by sale or transfer of more than 50% of its stock through a sale or merger, or a
sale of all or substantially all of its assets), or (c) as provided in the Joint
Venture Agreement. For purposes of this Agreement, a "Qualified Public Offering"
means a firm commitment underwritten Public Offering (as defined below) of
shares of the Company's Common Stock in which the net proceeds payable to the
Company shall be at least $50 million (before payment of underwriters' discounts
and commissions). "Public Offering" means any offering by the Company of its
equity or debt securities to the public pursuant to an effective registration
statement under the Securities Act of 1933, as then in effect, or any comparable
statement under any similar federal statute then in force (other than an
offering pursuant to a registration on Form S-4, S-8 or any comparable or
successor forms); or (c) the written consent of the parties to this Agreement.

      8. AGREEMENT BINDING. This Agreement shall inure to the benefit of and be
binding upon the Stockholders and each of their heirs, successors and permitted
assigns. It shall also be binding upon any transferee and their heirs,
successors and permitted assigns of such transferee who has received any Shares.

      9. ENTIRE AGREEMENT. This Agreement, the Joint Venture Agreement and the
documents listed in the Joint Venture Agreement constitute the entire agreement
of the parties as to the subject matter herein contained, superseding any and
all prior or contemporaneous oral and prior written agreements, understandings,
letters of intent or commitment letters.

      10. AMENDMENT OR WAIVER OF AGREEMENT. Except as otherwise expressly
provided herein, any term of this Agreement may be amended and the observance of
any term of this Agreement may be waived (either generally or in a particular
instance, either retroactively or prospectively and either for a specified
period of time or indefinitely) with the written consent of (a) the Company and
(b) each of the Stockholders. Any amendment or waiver effected in accordance
with this Section 10 shall be binding upon each Stockholder and each

<PAGE>

transferee of the Shares. Notwithstanding anything to the contrary in this
Section 10, subject to compliance with the terms of this Agreement, the Company
shall be entitled to include additional Stockholders as parties to this
Agreement in accordance with the provisions of Section 6 above, and to treat
such purchasers as Stockholders hereunder, by amending Schedule 1 attached
hereto and providing such Schedule 1, as amended, to the other parties to this
Agreement.

      11. NOTICES. All communications and notices provided for hereunder shall
be sent in accordance with the notice provision in the Joint Venture Agreement.

      12. GOVERNING LAW. This Agreement is made pursuant to, and will be
governed by and construed in accordance with, the laws of the State of Delaware
applicable to contracts executed and to be performed wholly within such state.

      13. INVALIDITY. If any portion or portions of this Agreement shall be
adjudged, declared, held, or ruled to be invalid for any reason, such invalidity
shall not be deemed to impair the validity of any other provision of this
Agreement.

      14. GENDER AND NUMBER REFERENCES. All references to any gender shall
include all genders; all references to the singular shall include the plural;
and all references to the plural shall include the singular, unless the context
indicates otherwise.

      15. REMEDIES. The parties hereto shall be entitled to enforce their rights
under this Agreement specifically, to recover damages by reason of any breach of
any provision of this Agreement and to exercise all other rights existing in
their favor. The parties hereto agree and acknowledge that money damages would
not be an adequate remedy for any breach of the provisions of this Agreement and
that the Company and any Stockholder may in its sole discretion apply to any
court of law or equity of competent jurisdiction for specific performance and/or
injunctive relief (without posting a bond or other security) in order to enforce
or prevent any violation of the provisions of this Agreement.

      16. BUSINESS DAYS. If any time period for giving notice or taking action
hereunder expires on a day which is a Saturday, Sunday or legal holiday in the
state in which the Company's chief executive office is then located, the time
period shall automatically be extended to the business day immediately following
such Saturday, Sunday or legal holiday.

      17. DESCRIPTIVE HEADINGS, ETC. The descriptive headings of this Agreement
are inserted for convenience only and do not constitute a part of this
Agreement. The use of the term "including" herein shall mean "including without
limitation."

      18. NO STRICT CONSTRUCTION. The parties hereto have participated jointly
in the negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as it was drafted jointly by the parties hereto, and no presumption or burden of
proof shall arise favoring or disfavoring any party hereto by virtue of the
authorship of any of the provisions of this Agreement.

<PAGE>

      19. COUNTERPARTS. This Agreement may be executed in multiple counterparts
(including by means of faxed signature pages), each of which shall be an
original and all which taken together shall constitute one and the same
agreement.

                           [Signature Pages to Follow]

<PAGE>

      IN WITNESS WHEREOF, the Common Stockholders and the Company have signed
this Agreement as of the day and year first above written.

                                    THE COMPANY

                                    ______________________

                                    By:____________________________________
                                    Name:__________________________________
                                    Title:_________________________________

                                    COMMON STOCKHOLDERS

                                    BRIDGETECH  HOLDINGS INTERNATIONAL, INC.

                                    By:  ___________________________________
                                    Name:
                                    Title:

                                    AMCARE LABS INTERNATIONAL, INC.

                                    By:  ___________________________________
                                    Name:
                                    Title:

<PAGE>

                                    EXHIBIT A

                              SIGNATURE PAGE TO THE
                              STOCKHOLDER AGREEMENT
                            DATED AS OF MAY __, 2005
                                NEWCO CORPORATION
                           AND ITS COMMON STOCKHOLDERS

      The undersigned hereby executes the Stockholder Agreement (the
"AGREEMENT"), authorizes this signature page to be attached as a counterpart of
the Agreement, and hereby agrees to be bound by the Agreement (which it
represents it has reviewed and understands); and this signature page, together
with the signature pages of and the other Stockholders shall constitute
counterpart copies of the Agreement in accordance with the terms of the
Agreement.

                                    ________________________________________
                                    Print Stockholder Name

                                    By:  ___________________________________
                                            Name:
                                            Title:
                                            Address:  ______________________
                                                      _____________________
                                                      _____________________

<PAGE>

                                   SCHEDULE 1

                          CAPITALIZATION OF THE COMPANY

<TABLE>
<CAPTION>
                                                SHARES OF         OWNERSHIP
              STOCKHOLDER                      COMMON STOCK       PERCENTAGE
---------------------------------------        ------------       ----------
<S>                                            <C>                <C>
Bridgetech Holdings International, Inc.
Amcare Labs International, Inc.
</TABLE>

<PAGE>

                                                                 SCHEDULE 6.1(c)

                               BRIDGETECH CONSENTS

None.

<PAGE>

                                                                 SCHEDULE 6.2(c)

                                 AMCARE CONSENTS

None.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00095-of-00352.parquet"}]]